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Abstract
Vitamin D plays a pivotal role in the regulation of calcium-phosphorus metabolism, particularly during pediatric age
when nutritional rickets and impaired bone mass acquisition may occur.
Besides its historical skeletal functions, in the last years it has been demonstrated that vitamin D directly or
indirectly regulates up to 1250 genes, playing so-called extraskeletal actions. Indeed, recent data suggest a possible
role of vitamin D in the pathogenesis of several pathological conditions, including infectious, allergic and
autoimmune diseases. Thus, vitamin D deficiency may affect not only musculoskeletal health but also a potentially
wide range of acute and chronic conditions. At present, the prevalence of vitamin D deficiency is high in Italian
children and adolescents, and national recommendations on vitamin D supplementation during pediatric age are
lacking. An expert panel of the Italian Society of Preventive and Social Pediatrics reviewed available literature
focusing on randomized controlled trials of vitamin D supplementation to provide a practical approach to vitamin
D supplementation for infants, children and adolescents.
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Background
Vitamin D plays a fundamental role in regulating calcium
and phosphorus homeostasis and, in particular, the path-
ways involved in bone mineralization and bone mass
acquisition. Besides these classic skeletal actions, recent
studies have demonstrated that vitamin D exerts other
significant extraskeletal actions, with a possible role in the
pathogenesis of several pathological conditions, including
infectious and autoimmune diseases [1]. The term ‘vitamin
D’ is used for two different forms which are found in
nature: vitamin D3 (cholecalciferol) from animal sources
and vitamin D2 (ergocalciferol) from plants. Humans
synthesize vitamin D3 in their skin in response to sunlight
exposure and vitamin D2 and D3 may be supplied from
dietary sources, although only a few foods contain
significant amounts (Table 1). Thus, with the exclusion of
artificially fortified foods, the contribution of dietary intakes
may be considered negligible [2, 3]. Previtamin D3 is
produced in the skin following ultraviolet B irradiation (at
wavelengths between 290 and 315 nm) of the 7-
dehydrocholesterol present in all the layers of human skin,
mainly in the epidermis. Previtamin D3 is an unstable mol-
ecule, subsequently transformed in vitamin D3 by a process
of thermo-conversion. Once previtamin D3 is synthesized
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in the skin, it can undergo also a photoconversion to lumi-
sterol and tachysterol, solar photoproducts inactive on cal-
cium metabolism that are produced at times of prolonged
exposure to solar UV-B radiation, to prevent sun-induced
vitamin D intoxication. Vitamin D2 and D3 are transported
by vitamin D binding protein to the liver, where they are 25-
hydroxylated by the vitamin D-25-hydroxylase (CYP2R1) to
produce 25-hydroxyvitamin D [25(OH)D], the major
circulating vitamin D metabolite which is used to evaluate
individual vitamin D status. Then 25(OH)D reaches the kid-
ney, where it undergoes a further hydroxylation by 25(OH)
D-1α-hydroxylase (CYP27B1) into 1,25-dihydroxyvitamin D
[1,25(OH)2D or calcitriol], the bioactive hormonal form of
vitamin D [2, 4]. Calcitriol is able to regulate calcium-
phosphorus balance in various pathways, first stimulating
calcium and phosphorus absorption by enterocytes. When
dietary calcium intakes are inadequate, calcitriol interacts
with the vitamin D receptor (VDR) expressed on osteoblasts,
bringing osteoclasts precursors to maturation and promoting
calcium and phosphorus absorption by bone tissue. Calcitriol
acts synergistically with parathormone (PTH) that acts in
bone stimulating calcium absorption by the osteoclasts, and
in the kidney where it promotes calcium reuptake in the
tubules, phosphorus excretion, and vitamin D conversion
into its active hormone form [2].
Methods
This document represents a consensus opinion of experts
derived from current literature revision and it is intended
to be mainly directed to hospital or primary care pediatri-
cians. The main objective is to give recommendations re-
garding the prevention and treatment of vitamin D
deficiency in Italian children and adolescents (0–18 years),
considering both the skeletal and extra-skeletal effects of
vitamin D and potential risk factors in specific subgroups of
children. The Working Group agreed on a list of relevant
clinical topics. Using the Consensus Conference method
based on the National Institutes of Health and the Italian
National Programme Guidelines [5, 6], relevant publica-
tions in English limited to the pediatric age (< 18 years)
were identified by a review of MEDLINE by PubMed, from
1st January 2005 to 1st August 2017, and using appropriate
search strategies for each topic. Checklists and predefined
tables were used to assess study quality and to extract data
in a standard way. Further literature search was performed
focusing available international guidelines on vitamin D
supplementation in children. The panel will be taking up
the issue again in 2 years, and will promote a new consen-
sus conference if clinically relevant evidence has emerged
from new studies. The full text of the guidelines and related
documents in Italian are available at the site of the Italian
Society of Preventive and Social Pediatrics [7].
Vitamin D deficiency: Ranges, analytic methods,
and epidemiology
The major circulating form of vitamin D is 25(OH)D,
having a half-life of 2–3 weeks. It is the best marker to
monitor for vitamin D status. In literature, several cut-offs
have been proposed for vitamin D deficiency with respect
to serum 25(OH)D levels measured with a reliable assay.
These cut-offs derive from PTH feedback threshold, cal-
cium intestinal absorption and bone health (presence of
rickets/osteomalacia, low bone mass and/or mineral con-
tent, fracture risk) [8–30] (Table 2). On the other hand,
the majority of the studies have been realized in adults.
Severe vitamin D deficiency is defined as 25(OH)D levels
< 10 ng/ml by several Authors and Societies because the risk
of rickets is high below this cut-off also in presence of an ad-
equate calcium intake [31–33] (see chapter “Nutritional rick-
ets”). The prevalence of rickets is also significant with
25(OH)D levels of 10–15 ng/ml in case of a low calcium in-
take [31, 33]. In the majority of studies in adults, 25(OH)D
levels of at least 20 ng/ml meet the needs of at least 97.5% of
the population with regards to bone health [10, 11], while
serum 25(OH)D levels ≥30 ng/ml are sufficient in about
100% of the adults [10, 11]. Secondary hyperparathyroidism
generally develops with 25(OH)D levels < 20 ng/ml, and
PTH levels reach a plateau at 25(OH)D levels of 30–40 ng/
ml [34–37]. However, some Authors showed that the rela-
tionship between PTH and 25(OH)D levels may be influ-
enced by many factors as age, gender, ethnicity, and weight
[38, 39]. Few studies evaluated the relationship between
25(OH)D and PTH in pediatrics, thus defining a threshold is
even more complex [40–48]. A study on 1370 Canadian in-
fants (1–6 years) observed the PTH plateau at 25(OH)D
levels > 42.8 ng/ml [49], whereas an Italian study on children
and adolescents reported a lower prevalence of secondary
hyperparathyroidism at 25(OH)D levels of 20–29 ng/ml, but
Table 1 Vitamin D content in some foods
Food Vitamin D average content (IU)
Milk and dairy products
Cow’s milk 5–40/l
Goat’s milk 5–40/l
Butter 30/100 g
Yogurt 2.4/100 g
Cream 30/100 g
Other Foods
Pork 40–50/100 g
Beef liver 40–50/100 g
Snapper (genus Dentex dentex), cod,
gilthead (Sparus auratus), dogfish
(Mustelus mustelus), sole, trout, salmon,
herring
300–1500/100 g
Cod liver oil 400/5 ml
Egg yolk 20/100 g
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no cases were detected above 30 ng/ml [50]. Moreover, no
clear evidence of a threshold for calcium absorption was
found with several 25(OH)D ranges in pediatrics. This could
be due by an age-dependent more efficient calcium absorp-
tion, a compensatory absorption vitamin D-independent and
a higher conversion to calcitriol [44, 51, 52]. Also when bone
health is considered, the studies are relatively small (see
chapter “Bone health”). A positive association between
25(OH)D levels, bone mineral content (BMC), and bone
mineral density (BMD) has been reported in children and
adolescents, in particular from the peripuberty, without a
specific threshold [53]. Moreover, a recent study in Chinese
infants (0–7 years) showed that when serum 25(OH)D levels
were above 30 ng/ml, the prevalence of low tibial BMD
(assessed by quantitative ultrasound) reached a plateau [54].
Based on the above considerations, we suggest to define vita-
min D status as reported in Table 3.
Vitamin D status is defined by the measurement of
25(OH)D concentrations. This term refers to both its
circulating forms, the 25(OH)D3 and 25(OH)D2, the last
from plant dietary sources. 1,25(OH)2D measurement does
not reflect vitamin D status, owing to the short half-life (4–
6 h) and the lower concentration (pg/ml vs. ng/ml).
1,25(OH)2D levels are reduced only when 25(OH)D levels
are below 4 ng/ml. The measurement of 25(OH)D is
difficult due to its lipophilic nature, the binding to vitamin
D binding protein, the different circulating forms that also
include epimers and isobars, and the standardization. In
particular, the 24,25-dihydroxyvitamin D may represent up
to 10–15% of the total quantity of 25(OH)D [55]. Various
Table 2 Definition of vitamin D status according to several Societies and Organizations in the last 10 years
Society/Organization Year Severe deficiency Deficiency Insufficiency Sufficiency/Adequacy
Canadian Pediatric Society [8] 2007 – < 10 ng/ml 10–29 ng/ml ≥ 30 ng/ml
Lawson Wilkins Pediatric Endocrine Society [9] 2008 < 5 ng/ml 5–14 ng/ml 15–19 ng/ml ≥ 20 ng/ml
Institute of Medicine [10] 2011 – < 12 ng/ml 12–20 ng/mla ≥ 20 ng/ml
The Endocrine Society [11] 2011 – < 20 ng/ml 21–29 ng/ml ≥ 30 ng/ml
British Paediatric and Adolescent Bone Group [12] 2012 – < 10 ng/ml 10–19 ng/ml ≥ 20 ng/ml
French Society of Paediatrics [13] 2012 – < 20 ng/ml – ≥ 20 ng/ml
Asociación Espanola de Pediatría (Spain) [14] 2012 – < 20 ng/ml – ≥ 20 ng/ml
Federal Commission for Nutrition (Switzerland) [15] 2012 < 10 ng/ml < 20 ng/ml – ≥ 20 ng/ml
Nordic Nutrition Recommendations [16] 2012 – < 12 ng/ml 12–20 ng/ml ≥ 20 ng/ml
German Nutrition Society [17] 2012 – – – ≥ 20 ng/ml
Health council of the Netherlands [18] 2012 – – – ≥ 12 ng/ml
European Society for Paediatric Gastroenterology
Hepatology and Nutrition [19]
2013 < 10 ng/ml < 20 ng/ml – ≥ 20 ng/ml
Central Europe [20] 2013 – < 20 ng/ml 20–29 ng/ml ≥ 30 ng/ml
Society for Adolescent Health and Medicine [21] 2013 – < 20 ng/ml 20–29 ng/ml ≥ 30 ng/ml
Australia/New Zealand [22] 2013 < 5 ng/ml 5–11 ng/ml 12–19 ng/ml ≥ 20 ng/ml
American Academy of Pediatrics [23] 2014 – < 20 ng/ml – ≥ 20 ng/ml
Japanese Society for Bone and Mineral Research,
Japan Endocrine Societyb [24]
2015 – < 20 ng/ml – –
Scientific Advisory Committee on Nutrition [25] 2016 – – – ≥ 10 ng/ml
European Food Safety Authority [26] 2016 – – – ≥ 20 ng/ml
United Arab Emirates [27] 2016 – < 20 ng/ml 20–29 ng/ml ≥ 30 ng/ml
Global Consensus for rickets [28] 2016 – < 12 ng/ml 12–19 ng/ml ≥ 20 ng/ml
Japanese Society for Bone and Mineral Research,
Japan Endocrine Societyc [29]
2017 – < 20 ng/ml 20–29 ng/ml ≥ 30 ng/ml
European Academy of Pediatrics [30] 2017 Definition of vitamin D status is unclear due to a lack of consensus
avitamin D inadequacy
bDiagnostic criteria for rickets
cAssessment criteria for vitamin D deficiency/insufficiency (authors reported that different criteria may be needed for children)
Table 3 Cut-off points for the definition of vitamin D status
based on circulating levels of 25(OH)D
Severe
deficiency
Deficiency Insufficiency Sufficiency
25(OH)D < 10 ng/ml
(< 25 nmol/l)
< 20 ng/ml
(< 50 nmol/l)
20–29 ng/ml
(50–74 nmol/l)
≥ 30 ng/ml
(≥ 75 nmol/l)
Conversion factor: ng/ml = nmol/l*0.401; nmol/l = ng/ml*2.496
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methods are available for determining 25(OH)D concentra-
tion, from the low-throughput radioimmunoassay tech-
niques to the new automated immunoassays with high
capacity, which in some cases still present poor accuracy
and precision [56, 57].The National Institute of Standards
and Technology has developed the stock standards for the
measurements of 25(OH)D3/D2 levels through isotope-
dilution liquid chromatography-tandem mass spectrometry
(LC-MS/MS) methods [58]. The issue of international
standardization of serum 25(OH)D measurement is also
being progressed by the Vitamin D Standardization Pro-
gram. The standardization, also retrospectively, should help
to develop future vitamin D guidelines [59, 60]. The
isotope-dilution LC-MS/MS is the standard method to al-
ways use in the neonates, because it is able to detect the
serum C3 epimer of 25(OH)D3, that may represent up to
the 40% of the total quantity of 25(OH)D [61–63]. When a
patient is under treatment with ergocalciferol, measure-
ments able to detect 25(OH)D2 are needed to avoid the risk
of hypervitaminosis D [64]. Because LC-MS/MS methods
are not so frequently used in clinical practice, at the mo-
ment other reliable assays could be used and certified la-
boratories are suggested. The measurement of free 25(OH)
D has not been standardized. Moreover, current algorithms
to calculate free 25(OH)D may not be accurate [65].
Hypovitaminosis D and vitamin D deficiency, inde-
pendently from cut-off definitions, have a higher preva-
lence worldwide in any age. In pediatrics, US data
derived by the National Health and Nutrition Examination
Survey cohort indicate a prevalence ranging 9–18%, and
51–61% of vitamin D deficiency and hypovitaminosis D,
respectively [66, 67]. A recent meta-analysis was con-
ducted on all the cohort studies of the European popula-
tion, basing also on a pediatric population of 14971
subjects (1–18 years) [68]. The Authors applied the Vita-
min D standardization Program and developed protocols
for standardizing existing 25(OH)D values from national
health/nutrition surveys. The prevalence according to age
(1–6 years, 7–14 years, and 15–18 years) ranged 4–7%, 1–
8%, and 12–40%, respectively, suggesting that particular
attention should be kept not only in infants but also in ad-
olescents. Non-white subjects and those living at relatively
mild-latitude countries (47–60° N) had a higher preva-
lence range (5–20%) than southern countries. Limitations
of the study include the fact that some of the studies
mainly included children aged 7–11 years, and that vita-
min D supplements, food fortification or sun awareness
campaigns could have influenced the estimates. Data from
Italian pediatrics are only limited being represented by the
Roma cohort (12.5–17.5 years) included in the HELENA
study [68].
Other Italian data are present in literature, although
they show some limitations, regarding small populations,
analytic methods for 25(OH)D, the season of recruitment,
the prevalence of overweight/obesity, vitamin D supple-
ments, sunscreens, ethnicity, and uncovered areas of lati-
tude. Despite these points, Italian data are in line with
those reported above, with higher prevalence in neonates,
in particular in those not Caucasian, in adolescents and in
overweight/obese subjects [50, 69–84]. Interestingly, also
the more limited estimates in southern Italy parallel those
of northern areas. Table 4 summarizes published studies
in Italian populations.
Sources of vitamin D and dietary reference values
Most of the vitamin D we synthesize (90%) starts with skin
exposure to ultraviolet B radiation from the sun. Cutane-
ous vitamin D3 production is influenced by several factors,
such as skin pigmentation, latitude, altitude, seasonality,
daily timing of sun exposure, atmospheric pollution, per-
centage of skin area exposed, type of clothing, and sun-
screen use. Children require less sunlight exposure than
adults to produce sufficient quantities of vitamin D, both
because of their higher body surface-area-to-volume ratio
and of their increased capacity to produce vitamin D [85].
In Italy children are unable to synthesize vitamin D in the
skin during late fall, winter months and early spring, even
if sufficiently exposed to sunlight [50]. Thus, during this
period an adequate vitamin D status can be maintained
only from endogenous stores accumulated during previ-
ous summer or by exogenous supplementation.
Breast milk represents the best food to satisfy chil-
dren’s nutritional needs, although it contains insufficient
amount of vitamin D (< 50 IU/l) [86]. Vitamin D intake
of formula fed infants varies according to the vitamin
content (about 400 IU/l) and daily formula intakes. Con-
sidering water requirements, formula fed infants may re-
ceive 400 IU/day of vitamin D, which is adequate for the
first year of life [10], only when they come to weigh 5 to
6 Kg. However, children are weaned by the time they
reach this weight and this further reduces their daily
milk consumption [1].
Most foods contain little amounts of vitamin D, with the
exception of some fatty fish (Table 1), rarely eaten by chil-
dren [9, 87]. Thus, dietary sources of vitamin D should not
be considered significant for humans except some popula-
tions living at higher latitudes where fish, fish oil and fish
eggs are frequently consumed [88]. In Italy, few commercial
milks or yoghurts are supplemented with vitamin D and/or
calcium. Nonetheless, despite the presence of this vitamin
in fortified milk, amounts can be insufficient in respect of
recommended intakes and needs. These foods, therefore,
fail to represent an optimal solution for the prevention of
vitamin-D deficiency among children and adolescents [50].
In the last years various Organizations and Societies
[10, 11, 16–18, 25, 26, 89] revised dietary reference
values of vitamin D in infants, children, and adolescents,
as reported in Table 5. In 2016 the United Kingdom
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Scientific Advisory Committee on Nutrition (SACN)
reviewed the evidence on vitamin D and health and rec-
ommended that serum 25(OH)D levels of all children
and adolescents in the United Kingdom should not fall
below 10 ng/ml (a so-called “population protective
level”) at any time of the year to protect musculoskeletal
health. Assuming minimal sunshine exposure, SACN
recommended a safe intake of 340–400 IU/day of vita-
min D for infants under 1 year of life, a safe intake of
400 IU/day for age 1 up to 4 years, and a reference nu-
trient intake of 400 IU/day for the United Kingdom
population aged 4 years and above [25]. In 2016 also the
European Food Safety Authority (EFSA) revised dietary
reference values for vitamin D. Considering a serum
25(OH)D levels of 20 ng/ml as a suitable target value,
under conditions of minimal cutaneous vitamin D syn-
thesis EFSA recommended an adequate intake of
400 IU/day for infants aged 7–11 months and of 600 IU/
day for children aged 1–17 years [26]. While there is suf-
ficient global agreement in considering 400 IU/day as
dietary reference value for vitamin D during the first
year of life, recommended reference values for children
and adolescents (1–18 years) slightly differ between
Organizations and Societies, reflecting different ap-
proaches and methods applied to calculate them.
However, various dietary reference values for vitamin D
are useful to guide local strategies for vitamin D supple-
mentation, but are not directly comparable. Particularly,
the Endocrine Society guidelines focused on patients at
risk for vitamin D deficiency, recommending a vitamin
D daily requirement of 400–1000 IU in the first years of
life and of 600–1000 IU from 1 up to 18 years [11].
In accordance with the European Society for Paediatric
Gastroenterology Hepatology and Nutrition [ESPGHAN]
[19] and the European Academy of Pediatrics [30], we en-
dorsed Tolerable Upper Intake Levels of vitamin D pro-
posed by EFSA in 2012 (1000 IU/day for infants: 2000 IU/
day for children ages 1 to 10 years; 4000 IU/day for chil-
dren and adolescents ages 11 to 17 years) [90].
Vitamin D supplementation
0–12 months
Vitamin D supplementation in the first year of life is essen-
tial to ensure an adequate vitamin D status and to prevent
nutritional rickets. Indeed, newborns and infants are poorly
exposed to sunlight, as the Section on Dermatology of the
American Academy of Pediatrics (AAP) recommended that
infants younger than 6 months of age should be kept out of
direct sunlight and covered with appropriate protective
clothing and hats [91]. As previously discussed, breast milk
[86] and formula milk [1] contain insufficient amount of
vitamin D to prevent its deficiency. Moreover, newborns
from deficient mothers are at increased risk for vitamin D
deficiency as cord blood and neonatal 25(OH)D levels highly
correlate with maternal vitamin D status during gestation
[92, 93]. The importance of vitamin D supplementation
Table 5 Dietary reference values of vitamin D in infants, children, and adolescents as proposed by various Organizations and Societies
Organization/Society Year Country/Countries Dietary reference
value for vitamin D
0–12 months,
IU/day
1–18 years,
IU/day
European Food Safety
Authority [26]
2016 Europe AI 400 (7–11 months) 600 (1–17 years)
Scientific Advisory Committee
on Nutrition [25]
2016 United Kingdom Safe Intake (< 4 years) 340–400 400
RNI (4–18 years)
Nordic Nutrition
Recommendations [16]
2012 Denmark, Finland, Iceland, Norway, Sweden,
Faroe Islands, Greenland, Åland Islands
RI 400 400
German Nutrition Society [17] 2012 Germany, Austria, Switzerland AI 400 (infants) 800a (children)
Health Council of the
Netherlands [18]
2012 The Netherlands AI 400 400
Italian Society of Nutrition [89] 2012 Italy AI (< 12 months) 400 (6–12 months) 600
PRI (1–18 years)
Institute of Medicine [10] 2011 North America, Canada AI (< 12 months) 400 600
RDA (1–18 years)
The Endocrine Society [11] 2011 Worldwide Daily requirementb 400–1000 600–1000
AI Adequate Intake, the average observed daily level of intake by a population group of apparently healthy people that is assumed to be adequate
Safe Intake, a level or range of intakes considered to pose no risk of deficiency and below a level where there is a risk of undesirable effects
RNI Reference Nutrient Intake, the amount of a nutrient that is likely to meet the needs of 97.5% of the population
RI Recommended Intake, the amount of a nutrient that meets the known requirement and maintains good nutritional status among practically all (97–98%)
healthy individuals in a particular life stage or gender group
PRI Population Reference Intake, the level of nutrient intake sufficient to satisfy the needs of almost all (97.5%) healthy subjects in one specific population group
RDA Recommended Dietary Allowance, the estimated intake capable of satisfying the needs of 97.5% of the population
aAdequate intake with missing endogenous synthesis of vitamin D
bRecommended requirements for subjects at risk of vitamin D deficiency
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during the first year of life has been confirmed by the find-
ing that children not receiving supplementation have re-
duced serum 25(OH)D levels, particularly if exclusively
breastfed and during winter season [94–96].
Some studies evaluated the effect of daily vitamin D sup-
plementation at variable dosages (ranging from 200 to
1600 IU/day) on vitamin D status in children during the
first year of life [52, 62, 97–107]. The administration of
400 IU/day starting from birth was effective in maintaining
serum 25(OH)D levels ≥30 ng/ml [52, 62, 97–99, 103–107].
On the contrary, vitamin D supplementation at higher dos-
ages seemed to be associated with increased risk of hypervi-
taminosis D with hypercalciuria and hypercalcemia [62].
Daily vitamin D2 or D3 administration was equally effective
in increasing serum 25(OH)D levels [108]. Only few studies
evaluated the efficacy and safety of intermittent vitamin D
supplementation during the first year of life, particularly in
cases with low compliance [109–111], thus at present daily
supplementation remains preferred.
Various international Scientific Societies agree to rec-
ommend vitamin D supplementation during the first year
of life [9, 12–15, 19, 20, 22, 23, 27, 28, 30, 112–116]. Par-
ticularly, the Global Consensus on prevention of nutri-
tional rickets recommended the administration of 400 IU/
day of vitamin D for all infants from birth to 12 months of
age, independently of their mode of feeding [28]. The
same recommendation has been worldwide proposed also
by an Expert Position Statement on vitamin D in child-
hood [1], the Department of Nutrition for Health and
Development of the World Health Organization [116], the
ESPGHAN [19], the European Academy of Pediatrics
[30], and the vitamin D guidelines for United Arab
Emirates [27] and Central Europe [20]. These Societies
also agree that the administration of 400 IU/day is safe
and effective to prevent rickets and ensure an adequate
vitamin D status. The Endocrine Society recommended a
daily intake of 400–1000 IU of vitamin D in children
under 1 year of age at risk for vitamin D deficiency [11].
Regarding the preferred form of vitamin D for supplementa-
tion, the National Institute for Health and Care Excellence
guideline recommended vitamin D drops in infants and
young children [114], while other international Scientific
Societies did not make any specific recommendation.
Despite this global agreement on vitamin D supple-
mentation in the first year of life, several barriers to ad-
herence still exist, such as reluctance of mothers to give
their children daily supplementation, lack of knowledge
about vitamin D actions and the risk of nutritional rick-
ets, lack of awareness by health care professionals, as-
sumption that both breast milk and formula milk
provide sufficient vitamin D intake [116, 117].
In the present Consensus we recommend vitamin D sup-
plementation in all newborns independently of the type of
feeding, starting from birth and continuing throughout the
first year of life. Infants born at term without risk factors
for vitamin D deficiency should receive 400 IU/day of vita-
min D, while in the presence of risk factors for vitamin D
deficiency (Table 6) up to 1000 IU/day of vitamin D can be
administered. We recommend against using vitamin D
metabolites and their analogs (calcifediol, alfacalcidol,
calcitriol, and dihydrotachysterol) for the routine vitamin D
supplementation, as the administration of these compounds
increases the risk of hypercalcemia and is not able to main-
tain and/or restore vitamin D stores [118, 119].
Preterm
Preterm infants are at risk for calcium-phosphorus metab-
olism alterations, with possible development of osteopenia
of prematurity [120]. As the majority of calcium and phos-
phate accretion and fetal bone mineralization occur during
the third trimester of pregnancy, preterm infants are de-
prived of the physiological mineral intrauterine supply, with
consequent impaired bone mineralization and increased
fracture risk. Very low birth weight (VLBW) infants (birth
weight < 1500 g) are at significant risk of osteopenia due to
the frequent administration of drugs that adversely affect
bone mineralization (steroids, methylxanthines and di-
uretics) and prolonged period of immobilization and total
parenteral nutrition [121]. At present, the exact timing and
proportion of vitamin D-dependent absorption of calcium
and phosphorus in preterm infants is unknown [122]. How-
ever, after 24 weeks gestation maternal 25(OH)D crosses
the placenta and is metabolized to 1,25(OH)2D for endo-
crine and paracrine actions [123]. In addition to optimize
bone mineralization during fetal life, vitamin D status has
been associated with acute respiratory morbidity in preterm
infants born < 32 weeks gestation [124].
Relatively few international Scientific Societies gave rec-
ommendations on vitamin D supplementation in preterm
infants. In 2013 the AAP recommended a daily vitamin D
intake of 200–400 IU for VLBW infants, as their smaller
size may lead to a lower need for vitamin D to ensure ad-
equate serum 25(OH)D levels. Vitamin D intake should
be increased to 400 IU/day (up to a maximum of 1000 IU/
Table 6 Risk factors for vitamin D deficiency in the first year of life
• Non-Caucasian ethnicity with dark skin pigmentation
• Inadequate diets (i.e. vegan diet)
• Chronic kidney disease
• Hepatic failure and/or cholestasis
• Malabsorption syndromes (i.e. cystic fibrosis, inflammatory
bowel diseases, celiac disease at diagnosis, etc.)
• Chronic therapies: anticonvulsants, systemic glucocorticoids,
antiretroviral therapy, systemic antifungals (i.e. ketoconazole)
• Infants born from mothers with multiple risk factors for vitamin D
deficiency, particularly in absence of vitamin D supplementation
during pregnancy
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day) when weight exceeds 1500 g and the infant tolerates
full enteral nutrition [122]. Differently, considering the
high prevalence of vitamin D deficiency during pregnancy,
the ESPGHAN recommended for preterm infants a vita-
min D intake of 800–1000 IU/day during the first months
of life to rapidly correct fetal low serum 25(OH)D levels
[125]. Other authors and guidelines for Central Europe
recommended vitamin D supplementation in preterm
infants at higher dosages (400–1000 IU/day) than those
suggested for healthy term newborns [1, 9, 20, 126], but
such an intake should not be prolonged over the theoret-
ical term (40 weeks of post-conceptional age) due to the
potential risk of vitamin D intoxication [126].
Preterm infants may receive vitamin D from various
sources, such as parenteral nutrition, fortified human milk
or preterm infant formula, but it has been calculated that
without supplementation they do not receive 400 IU/day
of vitamin D until reaching a weight of 2–2.5 Kg [123] or
only 4 weeks after birth [127]. However, total vitamin D
intake from supplementation and feeding should be
assessed to avoid excess, particularly in VLBW infants.
Some studies evaluated the effect of vitamin D supple-
mentation at different doses in preterm infants of various
gestational age and birth weight [124, 128–146]. Vitamin D
supplementation at 400 IU/day has been generally retained
safe and effective in maintaining adequate serum 25(OH)D
levels in preterm infants [131, 132, 135, 139–141]. Studies
that evaluated vitamin D supplementation at 200 IU/day
gave conflicting results [128, 129, 134]. Finally, some studies
evaluated the effect of supplementation at higher doses
(800–1000 IU/day) [133, 135–137, 140–146]. Cho et al. re-
cently recommended vitamin D supplementation at 800 IU/
day to enhance vitamin D status during early hospitalization
in VLBW infants with serum 25(OH)D levels < 10 ng/ml at
birth [142]. Mathur et al. found that supplementation at
1000 IU/day for 6 weeks was more effective than 400 IU/
day in maintaining serum 25(OH)D levels with a lower inci-
dence of skeletal hypomineralization and better growth
[144]. However, other authors did not find any difference in
clinical outcome or in bone accrual in preterm infants re-
ceiving supplementation at higher doses [135–137, 143] and
advised to avoid prolonged supplementation at 1000 IU/day
for the risk of hypervitaminosis D [143, 145, 146]. Particu-
larly, Fort et al. suggested for extremely low gestational age
newborns an initial vitamin D supplementation at 800 IU/
day for 1–2 weeks to restore serum 25(OH)D levels
followed by a lower dosage (200 IU/day) [143].
In the present Consensus we recommend a total daily
vitamin D intake of 200–400 IU (including the amount
administered through parenteral nutrition, fortified breast
milk, and preterm formula) for preterm infants with a
birth weight < 1500 g. Vitamin D supplementation at 400–
800 IU/day is recommended for VLBW infants when they
reach a weight ≥ 1500 g and full enteral nutrition, and for
preterm infants with a birth weight ≥ 1500 g. After a post-
conceptional age of 40 weeks, recommendations for vita-
min D supplementation are equal to those for healthy
term infants.
1–18 years
The promotion of an adequate vitamin D status is im-
portant for older children and adolescents, as nutritional
rickets may develop during the entire pediatric age [28]
and vitamin D deficiency may negatively affect bone
health [25, 26]. Various studies evaluated different
regimens of vitamin D supplementation, but comparison
of results is complex due to heterogeneity in vitamin D
administration (dose, interval, and length of supplemen-
tation) and population enrolled (age, gender, ethnicity,
body mass index, latitude of the country of residence,
season of enrolment, and basal vitamin D status).
Most of the studies evaluated daily vitamin D supple-
mentation at doses ranging from 200 to 1000 IU/day [78,
147–164]. Supplementation at 400 IU/day for variable
length (up to 12 months) was usually insufficient in raising
serum 25(OH)D levels > 30 ng/ml [78, 147–149, 151–153,
160–162], particularly in subjects with vitamin D defi-
ciency. A recent RCT performed during winter showed
that a vitamin D intake up to 800 IU/day was required by
white Danish children (4–8 years) to maintain serum
25(OH)D > 20 ng/ml. Particularly, subjects receiving
800 IU/day for 20 weeks increased their 25(OH)D levels
from 23.2 ng/ml to 30.3 ng/ml [161]. Another RCT dem-
onstrated that white UK adolescents (14–18 years) re-
quired higher intake of vitamin D (up to 1200 IU/day)
during winter to achieve 25(OH)D concentration > 20 ng/
ml in 97.5% of cases. Indeed, children and adolescents
supplemented with 800 or 1000 IU/day for 20 weeks in-
creased their 25(OH)D levels but frequently remained in-
sufficient [156–158, 162–164], while supplementation at
300 IU/day for 7 weeks did not result efficacious in youn-
ger children [163]. A few studies evaluated intermittent
regimens of supplementation (weekly, monthly, every 2–
6 months) in older children and adolescents, with conflict-
ing results [165–175]. Intermittent vitamin D administra-
tion may be considered in case of reduced compliance
with daily supplementation, but actual evidence is insuffi-
cient to recommend a preferred doses and interval.
Several international Societies recommended vitamin D
supplementation in children older than 1 year and adoles-
cents with risk factors for vitamin D, such as reduced sun
exposure or dark skin pigmentation [8, 9, 11, 18, 19, 23, 28,
30, 114]. Particularly, the ESPGHAN reinforced that first of
all a healthy lifestyle associated with a normal body mass
index and including a healthy diet with vitamin D-
containing foods and adequate outdoor activities should be
promoted in healthy children and adolescents [19]. More-
over, pediatricians should periodically evaluate vitamin D
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intake from diet and supplements [23, 28]. Considering the
Italian Child Health Care System organization, family pedi-
atricians may anamnestically evaluate vitamin D intake of
children and possible risk factors for deficiency during peri-
odic health check-ups [176].
On the contrary, other Societies systematically recom-
mended vitamin D supplementation in children and ado-
lescents during winter months [13, 20, 115] or
throughout the whole year if reduced sun exposure dur-
ing summer [20, 115]. Following the publication of
SACN review of the evidence on vitamin D and health
[25], Public Health England advised that UK children
aged 1 to 4 years should receive vitamin D supplementa-
tion at 400 IU/day, and older children and adolescents
should take a daily supplement containing 400 IU of
vitamin D in autumn and winter to protect bone and
muscle health because it is difficult to meet this intake
from dietary sources. Public Health England also recom-
mended that individuals with darker skin and people
with reduced sun exposure should receive vitamin D
supplementation throughout the year [115].
Adolescents are at increased risk for vitamin D deficiency
[79], thus the Society for Adolescent Health and Medicine
recommended continuous vitamin D supplementation
(600 IU daily for healthy adolescents, and at least 1000 IU
daily for adolescents at risk for vitamin D deficiency or in-
sufficiency) in addition to vitamin D received through the
diet or via sun exposure [21].
Variation of sunlight efficacy in promoting skin vitamin
D synthesis (depending on season and latitude) and local
factors related to sunlight exposure (i.e. cultural habits)
should be taken into account when considering supplemen-
tation [30, 177, 178]. For example, Arab Emirates guidelines
recommended vitamin D supplementation between May
and October because Arabian people avoid sun exposure
during summer due to excessive heat [27]. Regarding Italy
(latitude 35°29′24″-47°5′31″), an in vitro study showed
that no vitamin D is produced as a result of sun exposure
at the latitude of Pisa (43°43’N) from November to Febru-
ary [179], confirming that sunlight-derived vitamin D pro-
duction is ineffective for at least 1 month during the year in
countries placed between 23.5° and 66.5° of latitude [180].
Subsequent Italian cross sectional studies enrolling children
and adolescents living in the north-western area of
Tuscany, Central Italy (latitude between 43°N and 44°N)
not receiving vitamin D supplementation confirmed sea-
sonal variability in serum 25(OH)D levels, with lower con-
centrations during late winter-early spring months
(February–April), with negligible amount of vitamin D ob-
tained from diet [50, 79], according to other Italian
pediatric studies [70, 76–78, 83]. These data suggest that
wintry vitamin D status depends on the amount of vitamin
D produced and stored during the previous summer [181].
Finally, a recent cross sectional study showed high
prevalence of vitamin D deficiency and insufficiency (40.3%
and 33.5%, respectively) among internationally adopted
children at their first clinical evaluation in Italy [182].
In the present Consensus we recommend vitamin D
supplementation in children and adolescents with risk
factors for vitamin D deficiency (Table 7), at doses ran-
ging from 600 IU/day (i.e. in presence of reduced sun
exposure) up to 1000 IU/day (i.e. in presence of multiple
risk factors for vitamin D deficiency). In cases of poor
compliance, supplementation with intermittent dosing
(weekly or monthly doses for a cumulative monthly dose
of 18000–30000 IU of vitamin D) can be considered,
starting from children aged 5–6 years and particularly
during adolescence. Considering the results of Italian
studies, we suggest vitamin D supplementation from the
end of fall to the beginning of spring (November–April)
in children and adolescents with reduced sun exposure
during summer. Continuous supplementation should be
reserved to children with permanent risk factors for vita-
min D deficiency. Individuals on anticonvulsants, oral
corticosteroids, antimicotics and antiretroviral drugs
should receive at least 2–3 times more vitamin D than
the daily requirement recommended for age, in agree-
ment with the Endocrine Society [11] and the AAP [23].
As reported for infants in the first years of life, we rec-
ommend against using vitamin D metabolites and their
analogs (calcifediol, alfacalcidol, calcitriol, and dihydrota-
chysterol) for the routine vitamin D supplementation.
At present, population screening for vitamin D
deficiency in healthy individuals is not recommended.
Indeed, serum 25(OH)D evaluation should be reserved
to subjects at risk for vitamin D deficiency, but indica-
tions for 25(OH)D measurement significantly vary
among different societies (Table 8) [9, 11, 13, 15, 20–23,
27, 30]. We recommend against routine 25(OH)D test-
ing in children and adolescents, suggesting to limit
Table 7 Risk factors for vitamin D deficiency between 1 and
18 years of age
• Non-Caucasian ethnicity with dark skin pigmentation
• Reduced sunlight exposure (due to lifestyle factors, chronic illness
or hospitalization, complex disability, institutionalization, covering
clothing for religious or cultural reasons) and/or constant use of
sunscreens
• International adoption
• Obesity
• Inadequate diets (i.e. vegan diet)
• Chronic kidney disease
• Hepatic failure and/or cholestasis
• Malabsorption syndromes (i.e. cystic fibrosis, inflammatory bowel
diseases, celiac disease at diagnosis, etc.)
• Chronic therapies: anticonvulsants, systemic glucocorticoids,
antiretroviral therapy, systemic antifungals (i.e. ketoconazole)
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serum 25(OH)D levels evaluation in children and adoles-
cents with multiple risk factors for vitamin D deficiency.
Particularly, vitamin D status should be monitored at
least yearly in subjects that require supplementation
during the whole year because affected from pathological
conditions or receiving drugs affecting vitamin D metab-
olism (Table 7) (see “Extraskeletal actions of vitamin D”
for specific recommendations).
Table 8 Indications for 25(OH)D evaluation (besides rickets) in children and adolescents as proposed by various Organizations and Societies
Organization/Society,
year of publication
PES,
2008
[9]
ES,
2011
[11]
FCN,
2012
[15]
French Soc.
of Pediatrics,
2012a [13]
Australia -
New Zealand,
2013 [22]
Central
Europe,
2013 [20]
SAHM,
2013
[21]
AAP,
2014
[23]
Arab
Emirates,
2016 [27]
EAP,
2017
[30]
Frequent/low trauma fractures and/or low BMD X X X X X Xb X
Calcium/phosphate metabolism abnormalities X X
Immobilization/disabilities X X X X
Dark skin pigmentation Xc Xd X X X X X
Reduced sun exposure X X X X X
Athletes (indoor sports) X
Children institutionalized X X
Constant use of sunscreens X
Obesity X Xe X X X X
Inadequate diets (e.g. vegan) X X X
Elimination diets (e.g. cow/s milk allergy), eating
disorders
X X X
On anticonvulsants X X X X X X X X X X
On chronic glucocorticoids X X X X X X X
On HIV medications X X X X X
On antifungals (e.g. ketoconazole) X X X X
On rifampicin X X
Malabsorption syndromes X X X X X X X X X X
Chronic kidney disease X X X X X X X X X
Nephrotic syndrome X
Hepatic failure and/or cholestasis X X X X X X X X
Granulomatous disorders (e.g. tuberculosis) X X X X
Amenorrhea X
Cancer (different types) Xf X X X
Hepatitis Cg X X
Recurrent acute lower respiratory tract infectionsg X X
Atopic dermatitisg X X
Atopic Asthmag X X
Autoimmune diseasesh X Xi X
Cardiovascular diseases (especially hypertension) X X
Metabolic syndrome, type 2 diabetes X
PES Pediatric Endocrine Society, ES Endocrine Society, FCN Federal Commission for Nutrition (Switzerland), SAHM Society for adolescent health and medicine, AAP
American Academy of Pediatrics, EAP European Academy of Pediatrics
asuggested to guide vitamin D prescription in individuals with underlying risks requiring continuing supplementation all year long, if necessary
bgenetic conditions (osteogenesis imperfecta, idiopathic juvenile osteoporosis, Turner syndrome), endocrine conditions (Cushing syndrome, hypogonadism,
hyperthyroidism, hyperparathyroidism, growth hormone deficiency, diabetes mellitus) associated with reduced bone mass
cliving at higher latitudes in the winter and spring months
dAfrican-American and Hispanic children
eobese children with additional risk factors/symptoms for vitamin D deficiency
f some lymphomas
gpatients admitted to hospital
hmultiple sclerosis, psoriasis, rheumatoid arthritis, dermatomyositis, systemic lupus erythematosus
i systemic lupus erythematosus, juvenile idiopathic arthritis, juvenile dermatomyositis as associated with reduced bone mass
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Skeletal actions of vitamin D
Nutritional rickets
Rickets is characterized by defective mineralization of
developing bone tissue and reduced or absent endochon-
dral ossification of the growth plate, with subsequent de-
formation [183, 184]. Nutritional rickets is caused by
vitamin D deficiency and/or low calcium intake in chil-
dren. Despite a significant decrease in the incidence and
prevalence of nutritional rickets during the twentieth
century, new cases are still reported worldwide, both in
developing and industrialized countries [185, 186].
Children of immigrants living in industrialized countries
are at increased risk of rickets because they usually present
several risk factors for vitamin D deficiency such as pro-
longed breastfeeding without vitamin D supplementation,
increased skin pigmentation, reduced sun exposure due to
cultural habits (i.e. veiling), and reduced intestinal calcium
uptake due to an excessive intake of high-phytates foods
[187]. At present, no exact serum 25(OH)D threshold has
been defined below which nutritional rickets may develops
[33]. A recent global consensus recommendations on
prevention and management of nutritional rickets defined
vitamin D deficiency as serum 25(OH)D < 12 ng/ml, con-
sidering the increased incidence of rickets with serum
25(OH)D levels under this threshold [28]. Similarly, in 2016
the SACN reported that the risk of nutritional rickets
increased for serum 25(OH)D levels < 10 ng/ml [25].
Nutritional rickets diagnosis is based on the evaluation of
clinical, radiological and biochemical findings, as reviewed
elsewhere [9, 183, 188]. Rickets typically develops towards
the end of the first year of life and in the course of the sec-
ond year of life. Subsequently, the clinical signs of vitamin
D deficiency (i.e. rickety wrists and ankles, rachitic rosary,
Harrison’s sulci, lower limb deformities) become more sub-
tle. Particularly, adolescents may develop non-specific
symptoms, such as lower limb pain or difficulties in climb-
ing stairs, because of proximal myopathy secondary to vita-
min D deficiency [189]. Nutritional rickets may be
associated also with extraskeletal manifestations, such as
muscular hypotonia, delayed motor development, and in-
creased risk of respiratory infections. Moreover, vitamin D
deficiency may determine hypocalcaemia that may be
asymptomatic, latent or symptomatic possibly with acute
onset (seizures, syncope, laryngospasm, bronchospasm,
tetanus, paresthesia, tremors, muscular cramps, di-
lated cardiomyopathy) [188]. At X-rays osteopenia of
the long bones may be the earliest radiological sign of
rickets. Subsequently, a fraying and cupping deformity
of metaphyses following the proliferation of uncalci-
fied cartilage and osteoid tissue is usually observed
[190]. If nutritional rickets is suspected, biochemical
investigations [serum 25(OH)D, PTH, alkaline phos-
phatase, calcium, and phosphorus levels] and X-rays
evaluation of metaphyseal sites (wrists and ankles) are
recommended [188]. On the contrary, the evaluation
of serum 1,25(OH)2D and bone turnover markers is
not useful to pose diagnosis.
Vitamin D administration represents the main treatment
of nutritional rickets [183, 188], and some age-dependent
regimens have been proposed [9, 28, 183]. Oral treatment
is preferred as it more rapidly restores serum 25(OH)D
levels than intramuscular treatment [28]. The global con-
sensus on nutritional rickets recommended the administra-
tion of 2000 IU/day of vitamin D in patients aged less than
1 year, 3000–6000 IU/day in patients aged 1 to 12 years
and 6000 IU/day in patients older than 12 years for a mini-
mum of 3 months, even if some children may require a lon-
ger treatment duration [28]. Intermittent administration of
vitamin D may be a reliable alternative to daily administra-
tion, particularly in cases with low compliance. Indeed,
Munns et al. recommended a single dose of 50000 IU in
children age 3 to 12 months, 150000 IU in children aged 1
to 12 years, and 300000 IU in adolescents > 12 years of age.
When single large doses are used, vitamin D3 is preferable
compared to vitamin D2 because the former has a longer
half-life [28]. Monthly oral administration of 100000 IU for
three consecutive months was demonstrated to be safe and
effective to treat nutritional rickets in immigrant children
and adolescents living in Italy [187]. The administration of
a single large dose of vitamin D > 300000 IU is not recom-
mended, because may cause high risk of vitamin D intoxi-
cation with hypercalciuria and hypercalcemia, as confirmed
by recent studies [191–195]. After rickets healing, vitamin
D supplementation should continue according to age (at
least 400 IU/day in the first year of life and 600 IU/day
from 1 to 18 years) [11, 23, 28, 183, 188]. Besides vitamin
D, calcium is also important to treat nutritional rickets,
even in absence of hypocalcemia. Munns et al. recom-
mended oral calcium administration of 500 mg/day in con-
junction with vitamin D regardless of age or weight [28],
while Misra et al. recommended 30–75 mg/kg/day of elem-
ental calcium in 3 divided doses, starting at a higher dose
and weaning down to the lower end of the range over 2–
4 weeks [9]. Calcium should be administered intravenously
in presence of acute, symptomatic hypocalcaemia. Calcium
supplementation is important to prevent “hungry-bone”
syndrome (hypocalcemia secondary to an increase in bone
mineralization as PTH levels normalize during vitamin D
treatment) [9]. Vitamin D metabolites and their analogs
(calcifediol, alfacalcidol, calcitriol, and dihydrotachysterol)
are not recommended for treatment of nutritional rickets.
Particularly, the use of 1α-hydroxylated metabolites of vita-
min D does not restore vitamin D levels, and may deter-
mine supraphysiological levels of 1,25(OH)2D with
increased risk of hypercalcemia [183, 188]. The administra-
tion of 1α-hydroxylated metabolites of vitamin D may be
considered in nutritional rickets associated with acute
hypocalcemia or hypocalcemic cardiomyopathy [9, 183].
Saggese et al. Italian Journal of Pediatrics  (2018) 44:51 Page 12 of 40
Bone health
Bone mass acquisition is influenced by both genetics and
lifestyle-related factors, such as vitamin D status, physical
activity and calcium intake [23, 53]. Vitamin D contributes
significantly to bone mineralization by promoting intes-
tinal calcium and phosphorus reabsorption. Moreover,
vitamin D stimulates skeletal calcium and phosphorus and
renal calcium reabsorption. Besides the direct regulation
of calcium-phosphorus metabolism, vitamin D also
indirectly promotes bone mass accrual stimulating the de-
velopment of muscle tissue [196–198]. Bone mass acquisi-
tion starts during fetal life and continues throughout the
entire pediatric age until young adulthood with the
achievement of peak bone mass (PBM), that is the total
amount of bone mass acquired when accrual plateaus
after completion of growth and development [199]. As
bone mass tracks during childhood and adolescence, bone
status during pediatric age is a strong predictor of bone
status in young adulthood [200].
As discussed before, vitamin D supplementation during
the first year of life is essential to prevent nutritional rick-
ets occurrence. A few studies evaluated the relationship
between vitamin D status and bone mass during this
period of life [52, 62, 97, 104, 201–203]. Among these,
three Italian studies assessed bone mineral status in in-
fants using quantitative ultrasound [201–203], suggesting
that vitamin D supplementation is important to provide
an adequate bone development, particularly in exclusively
breastfed infants. On the contrary, studies using dual-
energy X-ray absorptiometry (DXA) or peripheral quanti-
tative computed tomography (pQCT) failed to demon-
strate an association between serum 25(OH)D levels and
bone mass parameters in the first year of life [52, 104].
Moreover, studies comparing supplementation with pla-
cebo or different regimens of vitamin D supplementation
(up to 1600 IU/day) did not find any difference in infant
bone mass at 3 months [104], 6 months [97], 1 year [62]
or 3 years of life [204]. Interestingly, higher vitamin D sta-
tus from infancy through to 3 years of age was associated
with leaner body composition [205]. Thus, vitamin D sup-
plementation during infancy is important to optimize
bone mass acquisition and body composition, but high
doses are not recommended.
Several studies evaluated the association between vita-
min D status and bone mass in children and adolescents,
usually searching for a correlation between actual serum
25(OH)D levels and bone mass. Results of these studies
are heterogeneous, because some demonstrated that vita-
min D status was significantly related to bone mass [41,
42, 54, 206–208] while others did not find any association
[44, 209–211]. Vitamin D status seems particularly im-
portant for bone health during adolescence. Indeed, duo-
denal expression of 25-hydroxyvitamin D3-1α-hydroxylase
is higher in adolescents than in children and adults,
representing a metabolic adaptation to promote dietary
calcium absorption for the growing bone [212]. A recent
study confirmed that serum 25(OH)D levels correlated
with bone density and bone quality pQCT parameters in
adolescents [213]. Moreover, vitamin D status was demon-
strated to be a significant determinant of PBM in young
adults [214, 215].
In 2010 a Cochrane meta-analysis of 6 randomized con-
trolled trials (RCTs) [148, 153, 166, 216–218] evaluated
the effect of vitamin D supplementation on BMD in
healthy children and adolescents (age 8–17 years, 541 sub-
jects receiving vitamin D and 343 receiving placebo)
[219]. Overall, meta-analysis showed a non-significant ef-
fect of vitamin D supplementation on BMD at any site.
However, the effect of supplementation became significant
on total body BMC and lumbar spine BMD by dividing
the sample into two groups, depending on vitamin D sta-
tus [25(OH)D levels < 14 ng/ml vs. ≥ 14 ng/ml], suggest-
ing that vitamin D supplementation may result in a
clinically significant increase in bone mass in subjects with
vitamin D deficiency. In 2016 the National Osteoporosis
Foundation applied an evidence based grading system to
describe the strength of available evidence on modifiable
lifestyle factors that may influence the acquisition of PBM,
reporting moderate evidence (grade B) for vitamin D
[220]. This systematic review selected 1 prospective study
[221], 3 cross-sectional studies [42, 222, 223], and 8 RCTs
of vitamin D supplementation. Five RCTs were already
evaluated by the Cochrane meta-analysis [148, 153, 166,
216, 217], while the remaining 3 studies were published in
2010 [147, 224, 225]. Particularly, 4 RCTs provide evi-
dence for a beneficial effect of vitamin D supplementation
on bone mineral accrual [148, 166, 216, 224], mainly in
subjects with vitamin D deficiency. In 2016, SACN and
EFSA revised dietary reference values for vitamin D
reporting an increased risk of adverse musculoskeletal
health outcomes at serum 25(OH)D levels in the range of
deficiency, but with different thresholds (< 10 ng/ml and
< 20 ng/ml, respectively) [25, 26]. Interestingly, a recent
study showed that the beneficial effect of vitamin D on
hip bone mass in Lebanese adolescent girls persisted 1 year
after discontinuation of supplementation [226]. At
present, some unanswered questions remain [critical times
during which supplementation may be most effective,
regimen and length of supplementation (continuous or
intermittent), gender difference] [227], thus vitamin D
supplementation to optimize bone mass acquisition
should be reserved for children at risk for deficiency.
Maternal vitamin D status during pregnancy may sig-
nificantly influence fetal and neonatal bone mass, as re-
cently confirmed by the SACN [25]. Particularly, fetal
bone growth was associated with maternal serum 25(OH)
D at 26 weeks [228] and 34 weeks of gestation [229]. New-
borns from mothers with serum 25(OH)D levels < 17 ng/
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ml (median value of the individual means for maternal
blood samples collected during the first trimester and
2 days postpartum) had higher tibia BMC and larger
cross-sectional area, as assessed by pQCT at 10 days post-
partum. These results confirmed that maternal vitamin D
status may affect bone mineral accrual during the intra-
uterine period and influence bone size [230]. Moreover,
postnatal vitamin D supplementation (follow-up
14 months) may only partly eliminate the differences in
bone variables induced by maternal vitamin D status dur-
ing the fetal period [231]. Recently an English RCT
(MAVIDOS) failed to demonstrate an effect of maternal
vitamin D supplementation (1000 IU/day from 14 week of
gestation until delivery) on offspring bone mass assessed
within 2 weeks of birth by DXA. However, secondary ana-
lysis showed a benefit for neonatal whole-body BMC (in-
creased by almost 10% vs. placebo) with supplementation
for deliveries during winter [232]. Women who gave birth
in winter had a mean 25(OH)D concentration of 12 ng/ml
at 34 weeks of gestation, suggesting a threshold at which
supplementation may significantly affect neonatal bone
mass [233]. Another smaller RCT on 50 newborns failed
to demonstrate an effect of vitamin D supplementation
during pregnancy (2000 IU/day from 26 to 28 weeks until
childbirth) on infant bone mass measured at 23 ± 10 days
by DXA [234].
Uncertain evidence exists on the relationship between
maternal gestational 25(OH)D levels and offspring bone
mass later in life (from 12 months to 10 years) [235–
239]. Several variables may justify this discrepancy, such
as different enrolled populations, various regimens of
vitamin D supplementation, and age at bone mass as-
sessment. However, the most recent study suggested that
vitamin D status during childhood might be more rele-
vant for bone health that maternal 25(OH)D levels dur-
ing fetal life [237].
Extraskeletal actions of vitamin D
Respiratory infections
Vitamin D has complex immunoregolatory properties,
exerted by modulating both innate and adaptive immunity
and regulating the inflammatory response. A relationship
between vitamin D status and the incidence or the severity
of respiratory infections in children has been found in
many observational studies, most with a case-control or
cross sectional design, both in developing and in western-
ized countries. Some systematic reviews have addressed
this topic as well [240–242]. The link between severe vita-
min D deficiency and susceptibility to respiratory infec-
tions is prototypically represented by the high respiratory
morbidity in children with rickets [243, 244]. Children
with rickets are more likely to develop pneumonia or poor
outcomes after lower respiratory infections [244, 245].
Other than pneumonia, some data also indicate that
vitamin D deficiency might be a risk factor also for undif-
ferentiated viral infections [246], recurrent pharyngoton-
sillitis [247], otitis media [248], bronchiolitis [249] and
viral wheezing [250]. Some authors also postulated that
the lower vitamin D production in winter might contrib-
ute to the marked seasonality of epidemic influenza [251].
Obviously, the more robust evidences on the association
between vitamin D deficiency and respiratory infections
stem from prospective studies. Camargo et al., after
adjusting for season of birth, found that newborns with
vitamin D cord blood levels < 10 ng/ml had a two-fold
(odds ratio: 2.16; 95% CI 1.35–3.46) increased risk of re-
spiratory infections by 3 months of age as compared to
newborns with 25(OH)D concentrations > 30 ng/ml [252].
Belderbos et al. also demonstrated that cord blood vitamin
D levels < 20 ng/ml were associated with a sixfold (95%
CI: 1.6–24.9) increased risk of respiratory syncytial virus
lower respiratory tract infections in the first year of life as
compared with concentrations ≥30 ng/ml [249]. Science
et al. in a cohort of 743 Canadian children aged 3–15 years
prospectively followed for 6 months found that 25(OH)D
D levels < 20 ng/ml increased the risk of laboratory con-
firmed viral infections by 70% [246]. Other studies have
found an inverse association between vitamin D concen-
trations in pregnancy and the risk of respiratory infections
in newborns or children during the first 3 years of life
[253, 254]. However, not all studies have confirmed these
associations [255, 256]. For example, no relationship has
been found in children and adults between baseline vita-
min D concentrations and influenza virus infection [256].
Taken together, all these data indicate that vitamin D
status might have some influence on conditioning the
incidence and severity of some but not all type of re-
spiratory infections and that more information are re-
quired before drawing any firm conclusion on this topic.
A recent literature review supports a role for vitamin D
deficiency only for tuberculosis, recurrent acute otitis
media and severe bronchiolitis [242]. Furthermore, some
role from VDR polymorphisms or other genetic factors
might play a role in determining the influence of vitamin
D status on respiratory morbidity [257, 258].
Several studies, mostly in adults, have also addressed the
question whether vitamin D supplementation can prevent
or reduce the severity of upper or lower respiratory infec-
tions. Systematic reviews with or without meta-analysis
[241, 259–266] also focused on this topic. Of those, four in-
cluded only studies in children [241, 263, 264, 266]. All but
two [259, 261] of the aforementioned reviews concluded
that published studies do not indicate a protective effect of
vitamin D supplementation on the prevention of acute re-
spiratory infections in healthy individuals. Some authors also
indicated a possible publication bias [261, 266]. However, a
well conducted study, not included in the above cited meta-
analysis, on a selected population of otitis prone children,
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found that vitamin D administration (1000 IU/day) reduces
the risk of uncomplicated acute otitis [267].
A recent meta-analysis of 25 RCTs (total 11,321 partic-
ipants, aged 0–95 years) showed that vitamin D supple-
mentation was safe and protected against acute
respiratory tract infections overall (adjusted odds ratio 0.
88). Subjects with severe deficiency [25(OH)D < 10 ng/
ml] and those receiving daily or weekly doses rather than
bolus dose had greater benefits [268], although the indi-
cation for this condition is still debated [269, 270]. In-
deed, a more recent Canadian RCT showed that daily
administration of 2000 IU of vitamin D did not reduce
overall wintertime upper respiratory tract infections
among healthy children aged 1–5 years compared with
supplementation with 400 IU/day. Thus, the results of
this study do not support the routine use of high-dose
vitamin D supplementation in children for the preven-
tion of viral upper respiratory tract infections [271]. Fi-
nally, limited data are available on vitamin D
supplementation in pregnancy and the risk of respiratory
infections in the offspring [272, 273].
Other infections
An association between serum 25(OH)D levels and several
types of pediatric infections has been reported. In a Turkish
study including 82 children with urinary tract infection and
64 healthy controls lower serum 25(OH)D concentrations
were evaluated, observing lower levels in infected children
[274]. Moreover, VDR gene polymorphisms can be import-
ant for susceptibility to urinary tract infection and renal scar
formation [275]. In an USA study a similar association was
observed between skin or soft tissue infections by Staphylo-
coccus aureus strains and vitamin D levels [25(OH)D <
30 ng/ml] in 202 children [276]. Other authors reported
similar findings in children with acute diarrhea [277], otitis
[277], rotavirus infection [278], malaria [279], leishmaniosis
[280], hepatitis C [281], or sepsis [282]. However, it is unclear
whether the observed vitamin D deficiency/insufficiency is to
be considered a consequence of the infection itself or if it
plays a role in determining susceptibility to infections or the
severity of the disease. Interpretations of study results should
also consider the different settings, the nutritional status of
the enrolled children and the prevalence of co-infections.
Few reports exist regarding the benefit of vitamin D
supplementation in children with specific infections. In a
large randomized study in Afghanistan involving 3000
children with acute diarrhea vitamin D supplementation
has been associated with improvement in clinical parame-
ters [283]. The interpretation of results conducted in hu-
man immunodeficiency virus (HIV) infected patient is
extremely complex. The vitamin D status can be influ-
enced by the infection itself but also by antiretroviral ther-
apy. Moodley et al. evaluated more than 900 infected
children and observed that vitamin D-related host genetic
variants may alter the availability and activity of vitamin D
and are associated with risk of HIV disease progression in
children [284]. In another study in Tanzania, serum
25(OH)D levels were evaluated in 884 pregnant women
and, subsequently, in their infants. Low maternal 25(OH)
D levels (< 32 ng/ml) were associated with a 46% higher
risk of mother to child transmission of HIV. Moreover,
children born from women with a low 25(OH)D level had
a 61% higher risk of dying during follow-up [285]. In a
large French study vitamin D deficiency was more fre-
quent in 113 children with HIV than in 54 healthy con-
trols [286]. Similar results were observed by Rustein et al.
in USA [287]. An Italian RCT was performed to test
whether vitamin D3 supplementation (oral 100000 IU
every 3 months for 4 doses) could improve vitamin D sta-
tus and affect the T-cell phenotype in HIV-infected pa-
tients aged 8 to 26 years with serum 25(OH) D < 30 ng/
ml. Supplementation increased 25(OH)D and 1,25(OH)2D
concentrations and decreased PTH levels but had no ef-
fect on CD4+ T-lymphocyte count. However, it was asso-
ciated with changes in CD4+ T-lymphocyte phenotype
[288]. In a pilot study in Botswana, vitamin D3 supple-
mentation (4000–7000 IU/day for 12 weeks) was safe and
improved vitamin D status, growth and HIV status [289].
Similarly, Dougherty et al. confirmed that a 7000 IU/day
D3 supplementation was safe and effective in HIV infected
children and young adults [290].
Tuberculosis is the infection probably more deeply stud-
ied at this regard [291–294]. Several studies investigated a
possible relationship between vitamin D deficiency and tu-
berculosis infection in children [295], but literature results
are discordant. Significant association between active tuber-
culosis and vitamin D deficiency [25(OH)D levels < 20 ng/
ml] has been evidenced in an Australian study including 91
children with latent or active tuberculosis and 236 controls
[296], similarly to one UK study [297]. A more recent large
study on 996 children serum 25(OH)D levels < 20 ng/ml
were more frequently observed in children with tubercu-
losis infection than in healthy controls [298]. Conversely,
such association was not confirmed in a smaller Indian
study [299]. Moreover, a large meta-analysis failed to dem-
onstrate that vitamin D supplementation may be beneficial
in children with tubercular infection [300]. Chiappini et al.
did not find an association between tubercular infection
and vitamin D status in a large population of internationally
adopted children, although results demonstrated a high
prevalence (about 75%) of hypovitaminosis D in this popu-
lation [182]. In the same study parassitosis was not related
to serum 25(OH)D levels. The same authors had previously
demonstrated a relation between tubercular disease and
vitamin D status [301]. However, it should be noticed that
only two internationally adopted children had active
tubercular disease, possibly explaining the discrepancy with
respect to previous results.
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These results are in line with those reported by Gro-
bler et al. in a Cochrane review in 2016. According to
this review, although blood levels of some vitamins may
be low in patients starting treatment for active tubercu-
losis, there is currently no reliable evidence that routine
supplementation at or above recommended daily
amounts has clinical benefits [302].
Asthma
Vitamin D status has also been linked with asthma develop-
ment and control [303]. Recently, Litonjua showed that
vitamin D has both in utero and post-natal effects on lung
development and immune system development and func-
tion [304]. Adverse exposures in this critical period, such as
low levels of serum 25(OH)D, might lead to developmental
changes including reduced lung and airway growth and
could therefore be a major importance for the development
of asthma. Vitamin D appears to affect innate and adaptive
immune system development through lymphocyte activa-
tion and proliferation, and T-helper cell differentiation
[305]. Several studies showed that vitamin D deficiency in
utero and in early life was associated with an increase in
Th2 lymphocyte cells and a reduction in T regulatory cells
and production of interleukin (IL)-10, which subsequently
may activate pro-inflammatory cytokine production
through macrophages and dendritic cells [306–308]. Con-
sequently, several studies in vivo and in vitro showed that
vitamin D supplementation inhibits the Th2 expression
contrasting allergic diseases [309–314]. Furthermore, previ-
ous studies focused on the association between serum
25(OH)D levels and the expression of genes involved in the
proliferation and cells differentiation, showing an anti-
proliferative activity of vitamin D with consequently re-
modeling inhibition [309–312]. Experimental data suggests
that vitamin D3 significantly overcame the inhibition of
glucocorticoid-receptor expression by dexamethasone while
IL-10 upregulated glucocorticoid-receptor expression by
CD4+ T cells, suggesting potential mechanisms whereby
these treatments may overcome poor glucocorticoid re-
sponsiveness [315]. About the role of vitamin D in the
immunopathogenesis of allergic skin diseases, vitamin D in-
duces the production of antimicrobial peptides, as beta-
defensin and cathelicidin, causing a reduction of the bacter-
ial infections that may exacerbate asthma and atopic
dermatitis (AD) [316, 317]. Not yet fully understood is the
role of vitamin D on eosinophilic airway inflammation. In a
recent study low 25(OH)D levels were associated to high
levels of fractional exhaled nitric oxide [318]. On the con-
trary, in a study on 3130 mother child pairs there was no
association between 25(OH)D levels and fractional exhaled
nitric oxide in the first month of life [319].
Several studies evaluated the incidence of asthma in chil-
dren and its relationship with 25(OH)D levels during preg-
nancy [320–323] and at delivery [252, 324]. Observational
studies on the relationship between vitamin D in pregnancy
and wheezing, asthma, and allergies development in early
life showed unclear results. Recently, two studies on 581
and 806 children respectively showed that 2800 IU/day or
4400 IU/day of vitamin D3 administered during the third
trimester of pregnancy compared to 400 IU/day did not
show any statistically significant reduction on the risk of
persistent wheezing in the offspring until 3 years of age
[325, 326]. These results were confirmed in other studies
that did not find without any correlation between serum
25(OH)D levels during pregnancy or at delivery and asthma
development [252, 320–322, 324]. On the other hand, the
study of Bener et al. in 966 children demonstrated that vita-
min D deficiency [serum 25(OH)D < 20 ng/ml] was the
major predictive factor of asthma risk [327], and Gale et al.
showed that gestational 25(OH)D levels > 30 ng/ml were
associated with an increased risk of asthma in children at
9 years of age [323].
Three studies evaluated 25(OH)D levels related to sever-
ity of asthma assessed by Asthma Control Test [328–330].
The first two studies showed that 25(OH)D levels were in-
versely related to asthma severity, while Gergen et al. dem-
onstrated a correlation only for Afro-Americans subjects.
Regarding asthma exacerbations, several studies evaluated
the association between 25(OH)D levels and the
hospitalization for asthma and/or asthma treatment with
oral steroids [330–333]. In most studies, low 25(OH)D
levels were associated with a rise in hospital admissions or
oral steroids treatment. A meta-analysis showed a significant
association between vitamin D supplementation and reduc-
tion of asthma exacerbations (17% vs. 46%, p < 0.029) [334].
Recently, three studies showed a positive correlation be-
tween vitamin D supplementation and the improvement of
asthma control [335–337], accordingly with two recent
meta-analyses. Vitamin D supplementation regimen chan-
ged in the studies between 500 and 2000 IU/day [338, 339].
Only the study of Lewis et al. did not show any correlation
between 25(OH)D levels and asthma control [340].
About the effects of vitamin D on lung function, a recent
meta-analysis demonstrated a difference of 0.54 l/s in
forced expiratory volume in the 1st second (FEV1) values
after the treatment with vitamin D [334]. In another study
high doses of vitamin D (100,000 IU as first dose and
50,000 IU/week for 6 months) were administered to 130
patients (children and adults). After 28 weeks the authors
showed an increase (20%) in FEV1 values in the patients
treated with vitamin D and corticosteroids in comparison
with an increase of 7% in the control group [341]. Vitamin
D supplementation at 2000 IU/day for 6 weeks in 39 chil-
dren with mild asthma and serum 25(OH)D levels < 30 ng/
m) did not showed significant variations in bronchial re-
activity or inflammatory markers (IL-4, IL-5, IL-10, IL-17,
and interferon-gamma) [342]. Two studies in vitro showed
the importance of vitamin D supplementation in patients
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affected by corticosteroid-resistant asthma [315, 343] but
two other studies demonstrated in vivo that lower 25(OH)
D levels were associated with an increase in corticosteroids
use and an impaired lung function [344, 345].
Atopic dermatitis and allergic diseases
Atopic dermatitis (AD) is a common chronic disease with
symptoms starting from the early childhood. It has been
observed in several studies that in moderate-severe AD
serum 25(OH)D levels are often reduced [346]. Being vita-
min D involved in innate immunity and in skin barrier in-
tegrity, and because both factors are dysfunctional in AD,
the association is actively debated. The evidences for a
pathogenetic role for vitamin D in AD are still conflicting
even though data in favour of such correlation are increas-
ingly stronger with more studies in favour but others op-
posing this hypothesis. However, at least two longitudinal
studies have correlated the vitamin D cord blood low
levels to the development of AD in the offsprings, finding
that low levels in the cord blood significantly increased
the risk to develop the disease [347, 348]. The lower intake
of vitamin D during early childhood increased the risk for
disease persistence during the mild childhood [348].
It is still a matter for full debate whether supplementa-
tion with vitamin D in pediatric AD is worth, particularly
in deficient patients. A recent large study found no evi-
dence that genetically determined reduction in 25(OH)D
levels conferred an increased risk for AD, suggesting that
efforts to increase vitamin D are unlikely to reduce risks
of the atopic disease [349]. However, there are also two re-
views and meta-analyses, considering AD patients of all
ages, showing that vitamin D supplementation is capable
of a higher mean difference in severity of AD symptoms
[350, 351]. Particularly, vitamin D supplementation de-
creased AD severity and improved its symptoms and clin-
ical signs. In pediatric population there is some evidence
about a favourable effect of administration of vitamin D
on several aspects of AD, but results are still conflicting.
For these reasons at present vitamin D supplementation
as adjunctive standard therapy for AD cannot be recom-
mended in all the affected children [351]. There is a need
for RCTs conducted on broader populations, with a pro-
longed follow up. However, it has been suggested that in
patients with a more severe AD, unresponsive to common
therapy and with low serum 25(OH)D levels, a trial of
vitamin D supplementation can be considered [352]. This
could be particularly indicated during the winter season
where the sun exposure is limited and ineffective and sup-
plementation not already suggested. Again, we need clin-
ical data showing that restoring normal levels of vitamin
D one can obtain significant variation in severity especially
if evaluated by standardized methods (symptom score,
Scoring Atopic Dermatitis or equivalent).
The so-called ecological studies suggest the relationship
between latitude, the consequent level of sun exposure,
vitamin D production and subsequent serum 25(OH)D
levels and the prevalence and severity of allergic diseases.
However, data from observational studies even though en-
couraging, are still controversial [353]. Furthermore, the
use of vitamin D supplementation for primary prevention
of allergic diseases remains an attractive area of study, but
current knowledge and evidence does not allow to recom-
mend it in routine use. Data from ongoing intervention tri-
als are warranted to establish the extent of vitamin D
potentially preventive effect, along with the best timing and
dose of an intervention.
Also in food allergies the role of vitamin D remains con-
troversial. There are studies suggesting that both lower and
higher levels of vitamin D are associated with elevated IgE
concentrations, with a U-shaped relationship [354].
However, evidences are still subtle and conflicting. A recent
systematic review failed to demonstrate a significant associ-
ation between serum 25(OH)D levels and food allergies
prevalence [355]. Negative results were obtained in term of
primary prevention by vitamin D supplementation in a re-
cent meta-analysis and conclusions were that the effects of
vitamin D supplementation remain uncertain [353]. There
is the need for RCTs to validate these hypotheses and to
evaluate the possibility of primary prevention and treatment
of food allergies with vitamin D [355–357].
Type 1 diabetes mellitus
Several epidemiological studies suggested that type 1
diabetes mellitus (T1DM) is associated with vitamin D
deficiency. A north-south gradient in the incidence of
T1DM as well as a seasonal pattern of disease onset have
been described. Low serum 25(OH)D levels are associated
to T1DM in children and adolescents independently by eth-
nic origins and environmental living conditions (latitude,
altitude) [358], persisting over time [359–366]. Moreover,
25(OH)D levels were lower in some but not all studies on
siblings at risk [367, 368]. Some studies suggest a linkage be-
tween polymorphisms of the VDR and T1DM with data
more convincing in Asians [369–371]. A recent large meta-
analysis focused only on pediatric populations revealed that
BsmIBB, BsmIBb and TaqItt polymorphisms were associ-
ated with an increased risk of T1DM, whereas BsmIbb and
TaqITT had protective effect [372]. Data on polymorphisms
of other genes involved in vitamin D metabolism are still
conflicting or related to small populations [373–376].
A meta-analysis of six case-control studies and two
cohort-studies showed a reduction of the risk of T1DM
in later life (odds ratio: 0.71; 95% CI 0.51–0.98) in in-
fants who were supplemented with vitamin D compared
with controls, although the needed time of supplementa-
tion and the dose are still unclear [377–379]. On the
other hand, data on supplementation in pregnancy are
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debated, and no evidence of protection has been shown
by recent meta-analyses [379, 380].
If data of observational studies in general population
in infancy are encouraging, in the DAISY study, con-
ducted in subjects at higher risk, the vitamin D nutri-
tional intake in the first years of life as well as the serum
25(OH)D levels at 9 months of age were not associated
with the development of autoantibodies or with the pro-
gression to T1DM [381]. Conversely, neonatal vitamin D
status seems to be associated to the risk of T1DM in
some [382] but not all the populations [383]. Moreover,
25(OH)D levels were not associated with a fast progres-
sion to T1DM later in life [368].
Until now, few clinical studies using cholecalciferol,
calcidiol, calcitriol or its analogs have been conducted in
the prevention or T1DM or in children with a recent
onset. They are small, short-term and often not random-
ized. The IMDIAB XI study in which new onset T1DM
children were given in the vitamin D group calcitriol at
0.25 μg/2 days or nicotinamide at 25 mg/kg/day re-
ported a reduction of insulin requirements in the vita-
min D group [384]. However, the IMDIAB XIII study in
which adolescents and young adults were given calcitriol
0.25 μg/day vs. placebo for 2 years failed to demonstrate
any improvement in T1DM [385]. Higher doses of cho-
lecalciferol (2000 IU/day, 4000 IU/day, 70 IU/Kg/day, or
14000 IU/month) improved the immunity status in small
populations with T1DM [386–389]. Similar data were
obtained with calcidiol for 1 year or calcitriol for
6 months in two pilot studies [390, 391].
Although some suggestive and encouraging data on
epidemiological observational studies and pilot clinical
studies of intervention, the lack of evidence deriving by
RCTs does not allow to encourage treatment with chole-
calciferol or other vitamin D metabolites in patients with
T1DM or subjects at higher risk. However, vitamin D
deficiency should be avoided in these populations.
Inflammatory bowel diseases
Vitamin D status has been associated with the pathogen-
esis of several autoimmune diseases, including inflamma-
tory bowel disease (IBD) [392–395]. Interestingly, the
incidence of pediatric Crohn’s disease increases with
higher latitude and greater number of months with low
ambient ultraviolet radiation [396], and some studies
showed high prevalence of hypovitaminosis D in IBDs
children and adolescents [397, 398]. A recent meta-analysis
showed that patients with Crohn’s disease (n = 129808, age
11–48 years) had lower serum 25(OH)D concentrations
compared with healthy controls, with an overall prevalence
of vitamin D deficiency [25(OH)D < 20 ng/ml] of 57.7%
and an inverse correlation between serum 25(OH)D levels
and the severity of disease [399]. The etiology of vitamin D
deficiency in patients with IBD is multifactorial and not
entirely known. Besides risk factors common to general
population (seasonality, reduced sun exposure, low dietary
vitamin D intake, etc.) subjects with IBD had increased risk
due to malabsorption, intestinal inflammation, protein-
losing enteropathy, and steroid treatment. Patients at early
stage of IBD, with more severe disease, and upper gastro-
intestinal tract involvement are at higher risk for deficiency
[398, 400–402].
Clinical guideline for skeletal health of children and
adolescents with IBD in 2011 recommended monitoring
vitamin D levels at least yearly, at the end of winter/be-
ginning of spring, especially in dark skinned subjects.
The authors suggested particular attention in children
with active IBD, low albumin level (< 3 g/dl), and evi-
dence of nutritional impairment [403]. The North
American Society for Pediatric Gastroenterology, Hepa-
tology and Nutrition [404] and other authors [405, 406]
also recommended to evaluate serum 25(OH)D levels in
IBD children at diagnosis and at least yearly, preferably
in the spring. A dietary assessment should also be rou-
tinely performed in IBD children, paying close attention
to the consumption of vitamin D-containing foods and
dairy products [404].
At present the ideal dosing regimen to treat vitamin D
deficiency and to maintain sufficiency in IBD patients is
still debated [406]. In IBD pediatric patients, 2000 IU/
day of vitamin D3 for 6 months was more effective in
raising serum 25(OH)D concentrations > 30 ng/ml than
400 UI/day or doses up to 2000 IU of vitamin D2 [407,
408]. On the other hand, supplementation with 2000 IU/
day of vitamin D3 for 13.8 months improved trabecular
BMD, cortical bone cross-sectional area, and maximal
muscle power in 55 IBD patients [409].
Regarding dose regimens, both oral doses of 2000 IU/
day of vitamin D3 and 50000 IU/week of vitamin D2 for
6 weeks were well-tolerated and superior to 2000 IU/day
of vitamin D2 in raising serum 25(OH)D concentration
IBD patients with vitamin D deficiency [410]. Simek et
al. found that two regimens of weekly vitamin D3 admin-
istration (5000 IU/10 Kg/week, maximum weekly dose
of 25000 IU and maximum cumulative dose of
150000 IU vs. 10000 IU/10 Kg/week, maximum weekly
dose of 50000 IU and maximum cumulative dose of
300000 IU) for 6 weeks were safe and effective in nor-
malizing vitamin D status in IBD children and adoles-
cents with hypovitaminosis D [411]. Finally, a single age
dependent high-dose oral vitamin D3 (the so-called stoss
therapy; < 3 years: 200000 IU; 4–12 years 400000 IU; >
12 years 800000 IU) was safe and efficacious in achieving
and maintaining serum 25(OH)D levels > 20 ng/ml dur-
ing a 6-month period in IBD children with vitamin D
deficiency [412].
Clinical guideline for skeletal health of children and
adolescents with IBD recommend to treat vitamin D
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deficiency and insufficiency administering a cumulative
dose of at least 400000 IU, and 250000 IU of vitamin D,
respectively. Vitamin D supplementation at 800–
1000 IU/day is suggested to maintain optimal vitamin D
status [403]. The Endocrine Society recommends to treat
vitamin D deficiency in patients with malabsorption with
vitamin D at doses 2–3 times higher than those recom-
mended for otherwise healthy pediatric population for at
least 6 weeks, followed by vitamin D supplementation at
doses 2–3 times higher than those recommended for age
[11]. Recently, Ahlawat et al. suggested to treat pediatric
IBD subjects with hypovitaminosis D at least with
2000 IU/day of vitamin D3, adjusting every 3 months de-
pending on serum 25(OH)D levels [406].
The role of vitamin D as a therapeutic agent in IBD is
still under investigation. Particularly, large RCTs are
needed to better investigate the role of vitamin D in dis-
ease remission and control.
Celiac disease
Celiac disease (CD) is caused by dysregulated systemic
and intestinal mucosal immune responses to dietary glu-
ten proteins in genetically predisposed individuals. It has
been suggested that early-life vitamin D deficiency may
contribute to the pathogenesis of childhood-onset CD by
determining inappropriate immune responses, abnormal
intestinal mucosal integrity and impaired local defence
against microbial agents [413]. A relationship between sun
exposure and CD pathogenesis has been suggested dem-
onstrating that CD was more common in US individuals
living at northern latitudes than at southern latitudes
(odds ratio 35°-39°N: 3.2; odds ratio ≥ 40°N: 5.4 vs. < 35°N)
[414]. On the contrary, maternal vitamin D supplementa-
tion, maternal and neonatal vitamin D status were not re-
lated to the risk of childhood CD [415, 416].
Vitamin D deficiency is common (up to 52%) in children
with CD at diagnosis [417–421]. Untreated CD is inde-
pendently associated with reduced BMD in children and
adolescents, as confirmed by US data from the National
Health and Nutrition Examination Survey 2009–2010 and
2013–2014 [422], with increased risk of osteoporosis and
fragility fractures in adulthood [423]. Indeed, small intes-
tinal mucosal damage may affect intestinal absorption of
calcium and vitamin D, and chronic intestinal inflamma-
tion may lead to release of proinflammatory cytokines
with subsequent increased bone loss [424]. Strict adher-
ence to gluten free diet results in recovery of BMD in both
children and adults [417, 425, 426], and the promotion of
an adequate vitamin D status is important to optimize
bone health in CD patients [419].
The American College of Gastroenterology [427] and
the British Society of Gastroenterology [428] recommend
serum 25(OH)D evaluation in adults with CD at the time
of initial diagnosis. The North American Society for
Pediatric Gastroenterology, Hepatology and Nutrition in
2016 recommend serum 25(OH)D evaluation also in CD
children at diagnosis and annually after symptoms reso-
lution and normalization of CD serology [429]. Recent
evidence-informed expert recommendations for the man-
agement of CD in children suggest to evaluate serum
25(OH)D levels at diagnosis, while follow-up evaluation is
needed only if previously abnormal (grade of evidence
low, strength of statement weak) [430]. Other authors
gave similar recommendations in a recent review [406].
Spontaneous recovery of vitamin D status following
gluten free diet has been suggested [417], but it is still
debated. Strict adherence to gluten free diet itself may
represents a determinant of vitamin D status, because it
has been demonstrated that Sweden CD children on glu-
ten free diet had low vitamin D intake compared with
Nordic Nutrition Recommendation and lower nutrient
density of vitamin D than healthy children [431].
As vitamin D is an important key determinant of bone
mass acquisition, some authors recommended vitamin D
supplementation during winter and spring in all CD
children and adolescents to optimize bone recovery
[432]. NICE guidelines advice that people with CD may
need to receive calcium and vitamin D supplementation
if their dietary intake is insufficient [433]. Other authors
reinforce that vitamin D supplementation should be of-
fered to CD patients at least during the first years of glu-
ten free diet [423]. Expert recommendations for the
management of CD in children recommended to provide
counselling on age-appropriate intake of calcium and
vitamin D supplementation by a dietitian to CD children
both at diagnosis and follow-up (grade of evidence high,
strength of statement strong) [430]. Future research will
clarify the ideal vitamin D dosing regimen to treat vita-
min D deficiency and to maintain serum 25(OH)D levels
≥30 ng/ml in CD children and adolescents [406].
Obesity and metabolic syndrome
Vitamin D status is influenced by adiposity because adi-
pose tissue represents a site of storage for lipophilic sub-
stances [434, 435]. In fact, obese children frequently show
reduced serum 25(OH)D levels [66, 436]. Particularly,
obese Italian children and adolescents have high preva-
lence of vitamin D deficiency and insufficiency [50, 71, 75,
78–80, 83, 84, 437, 438]. Two meta-analyses confirmed
that vitamin D deficiency was associated with obesity in
children, adolescents and adults irrespective of age, lati-
tude, and cut-offs used to define deficiency [439, 440].
Conversely, vitamin D deficiency does not lead to
obesity [441]. A recent meta-analysis of 4 RCTs and 11
non-RCTs, only 1 enrolling children [442], showed that
weight loss marginally improved vitamin D in compari-
son with weight maintenance under similar vitamin D
intake [443], confirming that increased adiposity causes
Saggese et al. Italian Journal of Pediatrics  (2018) 44:51 Page 19 of 40
suboptimal serum 25(OH)D concentrations. On the con-
trary, two meta-analyses enrolling mainly adults showed
that vitamin D supplementation did not decrease adipos-
ity [444, 445]. Animal models and in vitro studies report
that vitamin D may influence both pancreatic insulin se-
cretion and insulin sensitivity in skeletal muscle [446,
447]. Thus, several authors have suggested that vitamin
D deficiency could play a role in worsening the comor-
bidities of pediatric obesity. In 2009, Reis et al. reported
that obese children with lower serum 25(OH)D levels
had a higher risk for low high density lipoprotein choles-
terol, high blood pressure, and elevated fasting glucose
[448]. Few years later, Roth et al. showed an inverse rela-
tionship between serum 25(OH)D levels and insulin re-
sistance [449]. In 2007, Reinehr et al. reported no
correlation between insulin sensitivity and vitamin D
levels, even after weight loss [442]. Moreover, Erdönmez
et al. showed no difference in vitamin D status between
obese with or without impaired glucose homeostasis
[450]. Further, contrasting results came from the studies
investigating the association between vitamin D defi-
ciency and non-alcoholic fatty liver disease [451–453].
Several RCTs have been conducted to evaluate the
efficacy of vitamin D supplementation as a potential
therapy for each component of metabolic syndrome. In
a 16-week RCT with 2000 IU/day of vitamin D authors
reported that therapy was able to reduce arterial stiffness
in black obese adolescents [151]. Other papers describe
a significant reduction of insulin resistance index after
vitamin D supplementation [454, 455]. A prospective
study showed that high dose vitamin D2 treatment
(20000 IU/day for 28 days) increased insulin sensitivity
and improved abnormal glucose metabolism in obese
children [456]. More recent findings have reported no
influence of different vitamin D supplementation sched-
ules on serum lipid levels, glucose homeostasis, glycated
hemoglobin and pancreatic insulin secretion [457–459].
A recent Italian RCT showed that supplementation with
vitamin D (800 IU/day) plus docosahexanoic acid im-
proved insulin-resistance, lipid profile, aminotransferases
levels, and activity score in obese children with non al-
coholic fatty liver disease and vitamin D deficiency
[460]. Finally, two recent meta-analyses showed that
vitamin D supplementation had no significant effect on
glucose and insulin metabolism [461] and on changes in
the concentrations of inflammatory biomarkers (C-react-
ive protein, tumor necrosis factor alpha, IL-6) in obese
and overweight adolescents and adults [462].
At present the need for evaluate serum 25(OH)D
levels in obese children is still debated. The Endocrine
Society [11], United Arab Emirates guidelines [27] and
The Society for Adolescent Health and Medicine [21]
recommended to screen all obese children and adoles-
cents as they are at increased risk for vitamin D
deficiency. On the contrary, the AAP suggested that
more evidence is needed before recommendations can
be made regarding screening of obese subjects [23].
Different vitamin D dose regimens have been proposed
in obese children and adolescents for both vitamin D sup-
plementation and treatment of deficiency [463–467]. The
Endocrine Society Clinical Practice Guideline suggested in
obese children vitamin D supplementation at doses 2–3
times higher than those recommended for age to satisfy
their body’s vitamin D requirement. Similarly, obese chil-
dren with vitamin D deficiency should be treated with
vitamin D at doses 2–3 times higher than those recom-
mended for non-obese pediatric population for at least
6 weeks [11]. Similarly, Guidelines for Central Europe rec-
ommended in obese children vitamin D supplementation
(1200–2000 IU/day depending on severity of obesity) be-
tween September and April, or throughout the whole year
if sufficient skin synthesis of vitamin D is not ensured in
the summer [20]. Regarding adolescence, the Society for
Adolescent Health and Medicine recommended that
obese adolescent without a 25(OH)D measurement em-
pirically receive vitamin D supplementation at 1000 IU/
day [21]. More recently, United Arab Emirates guidelines
also recommended vitamin D supplementation in obese
children and adolescents (1200–2000 IU/day depending
on severity of obesity, season and sun exposure) through-
out the year if sufficient skin synthesis if vitamin D is not
ensured during winter [27]. Differently, SACN confirmed
that obese people are at risk of low serum 25(OH)D con-
centrations, but highlighted that currently evidence is in-
sufficient to recommend for obese individuals different
reference nutrient intake of vitamin D from that proposed
for the general UK population [25]. Recently, a double-
blind RCT analyzing the effects of vitamin D3 supplemen-
tation (1200 IU/day for 26 weeks vs. placebo) in over-
weight or obese children with hypovitaminosis D has been
proposed [468].
In conclusion, obese children have higher risk of vita-
min D deficiency and insufficiency. It is still unknown
the role of this nutrient in the natural history of obesity
and its comorbidities. More RCTs are needed to evaluate
the influence of vitamin D supplementation on control-
ling metabolic syndrome. Standardization of study de-
sign and supplementation dose should improve the
evaluation of the efficacy of supplementation. At present,
considering that obese Italian children have higher
prevalence of vitamin D deficiency and insufficiency
then normal weight individuals, we suggest in obese
children and adolescents vitamin D supplementation at
higher doses than those recommended for age (1000–
1500 IU/day) from the end of fall to the beginning of
spring (November–April) to ensure an adequate vitamin
D status. Obese subjects with reduced sun exposure dur-
ing summer should receive vitamin D supplementation
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throughout the year. Finally, sensible sunlight exposure
and outdoor physical exercise should be encouraged in
obese children and adolescents.
Autism and depression
Autism is a complex disease that compromises nonverbal
communication. Several observational studies have linked
autism spectrum disorders and low serum 25(OH)D levels
during pregnancy because of vitamin D pleiotropic activity
[469–476]. Moreover, autism spectrum disorders affect
dietary habits leading to food selectivity, thus patients could
develop multiple nutritional deficiencies [477–479]. Particu-
larly, a recent meta-analysis showed that serum 25(OH)D
levels in children and adolescents (age 2–16 years) with aut-
ism spectrum disorders were significantly lower than con-
trols, suggesting that lower vitamin D levels might be a risk
factor for autism [480]. Few studies or case reports suggested
that vitamin D supplementation can improve autism symp-
toms [481–484]. Nevertheless, a recent RCT enrolled 42
children with autism spectrum disorders showing that vita-
min D supplementation (2000 IU/day of vitamin D3 for
20 weeks) had no effect on the primary outcome (the stereo-
typic behaviour subscale from the Aberrant Behaviour
Checklist) in comparison with placebo [485]. Therefore, fur-
ther RCTs are needed before recommending routine vitamin
D supplementation in children with autism.
Depression affects about 1–6% of children [486]. Vitamin
D deficiency has been proposed as a possible cause of de-
pression. In fact, VDR is expressed in different brain’s areas
involved in the pathogenesis of the disease [487, 488].
Moreover, the severity of symptoms is higher in winter
when sun exposure is low [489]. Many studies report an as-
sociation between inadequate serum 25(OH)D levels and a
higher rate of depression or severity of symptoms both in
adults and children [490–492]. In contrast, Fazeli et al.
found no differences in vitamin D status and bone density
among adolescents affected by major depression and
healthy controls [493]. In agreement, Tolppanen and co-
workers reported no association between serum 25(OH)D
levels and any mood disorders [494]. A small Swedish study
showed that depressed adolescents with serum 25(OH)D
levels < 24 ng/ml supplemented with vitamin D3 (4000 IU/
day for 1 month followed by 2000 IU/day for 2 months)
improved symptoms related to depression [491]. Meta-
analyses assessing the effect of vitamin D supplementation
in depressed adults founded conflicting results [495–497].
As literature shows contrasting results because of different
methods and study designs, more studies are needed to de-
fine the role of vitamin D in pathogenesis and severity of
depression, particularly in the pediatric age.
Pregnancy and breastfeeding
The high prevalence of vitamin D deficiency in pregnant
women is a worldwide health problem regardless of
latitude, food intake or socio-economic status [93]. Data
about vitamin D intake and status in pregnant women
are relatively scarce but confirm this scenario. A recent
Italian study [81] evaluated serum 25(OH)D levels at
term of pregnancy in Italian and immigrant women and
in cord blood: 18% and 43.6% of Italian, 48.8% and 41%
of immigrant women had severe (< 10 ng/ml) or mild
(< 20 ng/ml) 25(OH)D deficiency, respectively. Likewise,
severe 25(OH)D deficiency was found in 38% of Italian
and in 76.2% of foreign newborns. Semi-quantitative
food questionnaires showed that the average dietary vita-
min D intake is 136 ± 68 IU, significantly lower than the
Institute of Medicine recommended amount (600 IU) [10].
Another Italian study [498] examined 24 women (light and
dark skinned) at full-term pregnancy: 23 out of 24 women
had vitamin D deficiency. Similarly, both light and dark
skinned babies showed vitamin D deficiency at birth.
During pregnancy vitamin D metabolism changes so that
maternal serum 1,25(OH)2D levels significantly rise to meet
increased calcium requirements for fetal skeleton
mineralization, whereas fetal vitamin D stores are exclu-
sively dependent on maternal vitamin D status. The in-
crease of 1,25(OH)2D in the mother plays a key role in
modulating calcium homeostasis in both mother and fetus,
first of all doubling maternal intestinal calcium absorption
[499]. Moreover, maternal bone turnover is reduced in the
first half of pregnancy, followed by the progressive increase
of bone resorption, reaching the maximum in the 3rd tri-
mester of pregnancy, to ensure fetal supply of calcium for
fetal bone development. In addition, vitamin D plays a key
role in the immunological adaptation needed for the onset
and maintenance of a normal pregnancy [500].
Increasing scientific evidence suggests that hypovita-
minosis D in the mother may have an impact on both
maternal and child health. Reduced 25(OH)D levels dur-
ing pregnancy and breastfeeding may affect maternal
bone turnover [501]. Moreover, maternal vitamin D defi-
ciency has been associated with increased risk of several
obstetrics diseases (spontaneous pregnancy loss, preterm
and/or small-for-gestational age birth, gestational dia-
betes pre-eclampsia) [502–506]. In addition, vitamin D
deficiency during pregnancy may negatively affect long-
term offspring extraskeletal health outcomes, with in-
creased risk of infant respiratory tract infections, asthma,
wheeze, and eczema [273, 380, 507, 508].
Vitamin D supplementation during pregnancy can im-
prove maternal and cord blood 25(OH)D concentrations
in women with low 25(OH)D levels [509]. Supplement-
ing pregnant women with vitamin D in a single or con-
tinued dose increases serum 25(OH)D at term and may
reduce the risk of preeclampsia, low birth weight and
preterm birth. However, larger and better-designed con-
trolled randomized trials are required to confirm these
effects [510].
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The Royal College of Obstetricians & Gynaecoloists
recommended vitamin D supplementation with 400 IU/
day for all pregnant women. Higher doses (at least
1000 IU/day) may be required in high-risk women
(women with increased skin pigmentation, reduced ex-
posure to sunlight, or those who are socially excluded or
obese) [511]. Indeed, vitamin D supplementation with
400 IU/day has been reported insufficient in pregnancy,
particularly for women at higher risk of vitamin D defi-
ciency [512, 513]. More recently, Wagner et al. sug-
gested that a vitamin D intake of at least 4000 IU/day
should be considered in all pregnant women to maintain
serum 25(OH)D levels ≥40 ng/ml [513, 514].
Screening for vitamin D deficiency during preg-
nancy is still debated. For example, the Endocrine So-
ciety considered gestation as a period at significant
risk for deficiency and thus recommended serum
25(OH)D evaluation in all pregnant women [11].
More recently, the Royal College of Obstetricians &
Gynaecoloists suggested to evaluate 25(OH)D concen-
trations during pregnancy in selected case (Table 9)
[511]. Moreover, the Society for Adolescent Health
Medicine recommended routine 25(OH)D testing in
pregnant adolescents [21].
In the present Consensus we recommend vitamin D
supplementation in all pregnant and breastfeeding
women since the beginning of pregnancy at a dose of
600 IU/day. Women with risk factors for vitamin D
deficiency should receive higher dosages (1000–2000 IU/
day). We do not recommend routine screening of serum
25(OH)D levels in all pregnant and breastfeeding
women, but we suggest to consider vitamin D testing in
women with multiple risk factors for vitamin D
deficiency, particularly if not receiving vitamin D
supplementation.
Appendix. Management of asymptomatic vitamin
D deficiency and insufficiency
In recent years some international Societies and Com-
mittees proposed various regimens to treat of vitamin D
deficiency [9, 11, 20–23]. The AAP recommended to
treat vitamin D deficiency administering 2000 IU/day or
50,000 IU/week of vitamin D2 or D3 (independent of
weight) for 6 week in infants (0–12 months) and for 6–
8 weeks in children and adolescents (1–18 years), sug-
gesting that vitamin D3 may be more potent than vita-
min D2 [23]. After completion of treatment, serum
25(OH)D concentrations should be revaluated, as it is
not unusual for a second course of treatment to be ne-
cessary to achieve adequate vitamin D status [23]. Par-
ticularly, maintenance therapy with standard doses or
with doses two or three times higher than those recom-
mended for healthy children is recommended after treat-
ment [9, 11, 20–23].
Relatively few studies evaluated the efficacy of different
regimens with vitamin D2 or vitamin D3 for the treatment
of vitamin D deficiency in otherwise healthy children.
Studies with daily or weekly regimens
In vitamin D deficient infants younger than 2 years, either
2000 IU of vitamin D2 or vitamin D3 daily or 50000 IU of
vitamin D2 weekly for 6 weeks equally increased serum
25(OH)D levels [515]. A recent RCT in children (2–
5 years) with vitamin D deficiency showed that treatment
with oral 4000 IU/day or 30000 IU/week for 12 weeks or a
single intramuscular dose of 300000 IU of vitamin D3
followed by a maintenance dose of 400 IU/day increased
and maintained serum 25(OH)D concentration > 30 ng/
ml after 1 year [516]. Daily administration of 2000 IU of
vitamin D3 for 16 weeks was effective in increasing serum
25(OH)D levels > 30 ng/ml also in black adolescents (14–
18 years) with vitamin D deficiency [151]. Another RCT
showed that adult-size adolescents require high-dose vita-
min D3 (at least 5000 IU/day for 8 week) to correct defi-
ciency [517]. Particularly, as discussed before, the
administration of 50000 IU/week for 6–8 weeks may be in-
sufficient to increase 25(OH)D concentration > 30 ng/ml in
obese children and adolescents [466, 517]. The administra-
tion of 60000 IU of vitamin D3 weekly for 4–8 weeks
followed by 600 IU daily for 12 weeks in Indian adolescents
[518] or a regimen of 60000 IU/week of vitamin D3 for
8 weeks followed by 60000 IU/fortnight in young Indian fe-
males [519] were both effective in increasing and maintain-
ing 25(OH)D levels in deficient individuals. Adolescents
treated with 14000 IU of vitamin D3 weekly (equivalent to
2000 IU daily) for 1 year normalized their 25(OH)D levels
[166, 167, 520]. A recent 1-year-RCT compared three differ-
ent regimens for asymptomatic children and adolescents
with vitamin D deficiency and insufficiency (400 IU/day,
45000 IU weekly for 2 months then 400 IU daily, 2000 IU/
Table 9 Indications for serum 25(OH)D evaluation during
pregnancy (modified from [511])
• Non-Caucasian ethnicity with dark skin pigmentation
• Reduced sunlight exposure (i.e. veiled women) and/or constant
use of sunscreens
• Malabsorption syndromes
• Chronic therapies affecting vitamin D metabolism
• Obesity
• Risk of pre-eclampsia
• Alcohol abuse
• Bone pain
• Hypocalcemia
• A previous child with rickets
• Pregnant adolescents
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day for 3 months then 1000 IU/day), suggesting that low
loading dose with high maintenance dose is preferred to
achieve steady increase in serum 25(OH)D levels avoiding
hypercalcemic side effects [521]. Lower doses as 200 IU/day,
400 IU/day, 800 IU/day [147, 153] or 1400 IU/week for 1 year
[166], 1000 IU/day for 6 months [159], or 5000 IU/week for
8 weeks [165] were not able to normalize 25(OH)D levels in
several pediatric populations, including Italian children and
adolescents supplemented with 400 IU/day for 1 year [78].
Studies with monthly or other regimens
The majority of these studies have been conducted in
small populations of adolescents. Several schedules have
been used, with conflicting results.
The administration of 60000 IU/month of vitamin D3
for 12 months in Indian children was effective in raising
25(OH)D concentrations > 30 ng/ml [171], while an-
other study showed that 60000 IU of vitamin D3
monthly or every 2 months for 12 months in Indian fe-
males (6–17 years) increased 25(OH)D levels in the
range of insufficiency [172]. Similarly, a RCT in Iranian
adolescents showed that 50000 IU/months of vitamin D3
for 5 months increased serum 25(OH)D levels but
remained insufficient [170]. Two studies evaluated the
efficacy of administering a bolus dose of vitamin D2,
150000 IU [225] or 300000 IU [224], every 3 months for
12 months in adolescent females with severe vitamin D
deficiency, with conflicting results. Indeed, only in the
study of Khadilkar et al. serum 25(OH)D concentrations
increased > 30 ng/ml. Adolescents with severe vitamin D
deficiency treated with an intramuscular injection of a
megadose of vitamin D3 (10000 IU/Kg, maximum
600000 IU) had insufficient serum 25(OH)D after
3 months [522]. Both 300000 and 600000 IU single oral
vitamin-D bolus were effecting in treating vitamin D de-
ficiency in young children (3 months-3 years) but a sig-
nificant percentage developed hypercalcemia and/or
hypercalciuria [195]. On the contrary a stoss therapy
(oral single-dose of 10000 IU/Kg or 300000 IU of vita-
min D3) has been demonstrated effective and safe in the
treatment of vitamin D deficiency in older children
(mean age 10.6 ± 4.4 years) without rickets [523]. How-
ever, at present safety data in both the short- and the
long-term of monthly or other vitamin D regimens lack
due to the nature of the studies, especially in young
children.
Different dose regimens have been proposed in condi-
tions and diseases known to be a risk for vitamin D defi-
ciency. However, all the studies have been conducted in
small populations.
Regarding children receiving anti-retroviral drugs,
Kakalia et al. found that in children infected with HIV
and vitamin D insufficiency a daily intake ≥1600 IU/day
of vitamin D3 vitamin D may be required to achieve
serum 25(OH)D levels > 30 ng/ml [524]. Higher doses of
4000 or 7000 IU/day of vitamin D3 for 6–12 weeks or
1 year increased 25(OH)D levels in the range of suffi-
ciency in the majority of the patients with a variable
prevalence of hypercalcemia which required no clinical
intervention [289, 525–527]. Differently, regimens with
50,000 IU monthly [528] or 100000 IU of vitamin D3
every 2–3 months normalized 25(OH)D levels only in a
half of the patients [288, 529, 530]. In children on long-
term antiepileptic drugs (valproate, lamotrigine, topira-
mate, clonazepam, gabapentin, carbamazepine, pheny-
toin, phenobarbital), the administration of 2000 IU/day
of vitamin D2 for 1 year slightly increased mean 25(OH)
D level from 18.0 ± 9.1 to 22.9 ± 8.4 ng/ml [531]. No tri-
als with different vitamin D2 or vitamin D3 regimens
have been conducted in children under chronic cortico-
steroid treatments. For treatment of vitamin D defi-
ciency in obese or IBD children see specific chapters.
At present there is no strong evidence about whether to
treat asymptomatic children with vitamin D insufficiency
[23]. The Society for Adolescent Health and Medicine rec-
ommended to supplement vitamin D insufficient with
vitamin D 1000 IU/day for at least 3 months [21]. In the
case of vitamin D insufficiency, particularly in subjects at
risk for vitamin D deficiency, we recommended starting
vitamin D supplementation according to the modalities
and requirements recommended for age.
Conclusions
Vitamin D status is a key determinant of bone health dur-
ing childhood and adolescence. Nutritional rickets cases
are still reported in Italy, thus adequate national strategies
to prevent vitamin D deficiency are needed. Moreover, the
recently suggested role of vitamin D in the development
of other non-skeletal diseases reinforced the interest in
the promotion of an adequate vitamin D status during
pediatric age. The present Consensus paper aims to give
practical approach to vitamin D supplementation for Ital-
ian infants, children and adolescents. Particularly, vitamin
D supplementation should be recommended in all infants
in the first year of life, independently of the type of feed-
ing. Supplementation should be subsequently individual-
ized in terms of regimen and duration on the basis of the
presence of risk factors for vitamin D deficiency. More
studies, particularly RCTs, are needed to confirm the
promising role of vitamin D in the promotion of the glo-
bal health of children.
Summary of recommendations
Definition of vitamin D status
 Individual vitamin D status can be assessed
evaluating serum circulating 25(OH)D levels.
Saggese et al. Italian Journal of Pediatrics  (2018) 44:51 Page 23 of 40
 Depending on 25(OH)D levels, vitamin D status can
be defined as follows:
Sufficiency ≥30 ng/ml
Insufficiency 20–29 ng/ml
Deficiency < 20 ng/ml
Severe deficiency < 10 ng/ml
 The term hypovitaminosis D refers to serum
25(OH)D levels < 30 ng/ml.
Evaluation of vitamin D status
 The isotope dilution- LC-MS/MS is considered the
preferred method for measuring serum 25(OH)D
levels, especially in the neonatal period. However,
considering the reduced availability on the
Italian territory of this method, other reliable
immunoassay methods can be used if performed
in certified laboratories, with the exclusion
of neonates.
Prevalence of hypovitaminosis D in Italy in pediatric age
 Available epidemiological studies show a high
prevalence of hypovitaminosis D (above 50%)
throughout Italy. Adolescents are particularly at risk
of hypovitaminosis D.
 Vitamin D status of newborns is influenced by
ethnicity, season of birth, and maternal vitamin D
status during pregnancy.
 Vitamin D status of children and adolescents is
influenced by sun exposure, seasonality, ethnicity,
and body mass index.
Vitamin D supplementation
0–12 months
 We recommend vitamin D supplementation in the
first year of life to ensure an adequate vitamin D
status and to prevent nutritional rickets.
 We recommend vitamin D supplementation in all
newborns independently of the type of feeding.
 Vitamin D supplementation should be started within
the first days of life and continued throughout the
first year.
 Infants born at term without risk factors for
vitamin D deficiency should receive 400 IU/day of
vitamin D.
 In the presence of risk factors for vitamin D
deficiency (Table 6) up to 1000 IU/day of vitamin D
can be given.
 In the first year of life we recommend daily
administration of vitamin D.
 We recommend against using vitamin D metabolites
and their analogs (calcifediol, alfacalcidol, calcitriol,
and dihydrotachysterol) for the routine vitamin D
supplementation. The administration of these
compounds increases the risk of hypercalcemia
and is not able to maintain and/or restore
vitamin D stores.
 We recommend against routine 25(OH)D testing in
infants in the first year of life. We suggest to
measure serum 25(OH)D levels in infants with
multiple risk factors for vitamin D deficiency
(Table 6).
Preterm infants
 We suggest for VLBW infants a vitamin D intake of
200–400 IU/day (including the amount administered
through parenteral nutrition, fortified breast milk, or
preterm infant formula).
 When VLBW infants reach a weight ≥ 1500 g and
full enteral nutrition we suggest vitamin D
supplementation at 400–800 IU/day.
 We recommend vitamin D supplementation at
400–800 IU/day for preterm infants with birth
weight ≥ 1500 g.
 After a post-conceptional age of 40 weeks,
recommendations for vitamin D supplementation
are equal to those for healthy term infants.
 We recommend against routine 25(OH)D testing in
preterm newborns.
1–18 years
 We recommend vitamin D supplementation in
children and adolescents with risk factors for
vitamin D deficiency (Table 7). Moreover, we
recommend to evaluate modifiable life-style risk
factors for deficiency, particularly a reduced sun
exposure. Ensuring an adequate vitamin D intake is
particularly important during adolescence.
 We recommend daily vitamin D supplementation
ranging from 600 IU/day (i.e. in presence of reduced
sun exposure) up to 1000 IU/day (i.e. in presence of
multiple risk factors for vitamin D deficiency).
 In cases of poor compliance, supplementation with
intermittent dosing (weekly or monthly doses for a
cumulative monthly dose of 18000–30000 IU of
vitamin D) can be considered, starting from children
aged 5–6 years and particularly during adolescence.
 We suggest vitamin D supplementation from the
end of fall to the beginning of spring (November–
April) in children and adolescents with reduced sun
exposure during summer. We suggest continuous
vitamin D supplementation in cases of permanent
risk factors for vitamin D deficiency.
 Individuals on anticonvulsants, oral corticosteroids,
antimicotics and antiretroviral drugs should receive
at least 2–3 times more vitamin D than the daily
requirement recommended for age.
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 We endorsed as Tolerable Upper Intake Levels of
vitamin D those proposed by EFSA in 2012
(1000 IU/day for infants; 2000 IU/day for children
ages 1 to 10 years; 4000 IU/day for children and
adolescents ages 11 to 17 years).
 We recommend against using vitamin D metabolites
and their analogs (calcifediol, alfacalcidol, calcitriol,
and dihydrotachysterol) for the routine vitamin D
supplementation. The administration of these
compounds increases the risk of hypercalcemia
and is not able to maintain and/or restore
vitamin D stores.
 We recommend against routine 25(OH)D testing in
children and adolescents. We suggest to measure
serum 25(OH)D levels in presence of multiple risk
factors for vitamin D deficiency. Vitamin D status
should be monitored at least yearly in subjects that
require supplementation during the whole year
because affected from pathological conditions or
receiving drugs affecting vitamin D metabolism
(Table 7).
Skeletal actions of vitamin D
Nutritional rickets
 Children of immigrants living in industrialized
countries are at increased risk of nutritional rickets
because they usually present several risk factors for
vitamin D deficiency such as prolonged
breastfeeding without vitamin D supplementation,
increased skin pigmentation, reduced sun exposure
due to cultural habits (i.e. veiling), and reduced
intestinal calcium uptake due to an excessive intake
of high-phytates foods.
 In suspicion of nutritional rickets we recommend
the assessment of serum 25(OH)D, parathyroid
hormone, alkaline phosphatase, calcium, and
phosphorus levels and an X-rays evaluation of
metaphyseal sites (wrists and ankles) to confirm
the diagnosis.
 Treatment of nutritional rickets is based on the
administration of vitamin D (2000 IU/day in patients
aged less than 1 year, 3000–6000 IU/day in patients
aged 1 to 12 years and 6000 IU/day in patients older
than 12 years for a minimum of 3 months) and
calcium (30–75 mg/kg/day of elemental calcium in 3
divided doses, starting at a higher dose and weaning
down to the lower end of the range over 2–4 weeks).
 Vitamin D metabolites and their analogs (calcifediol,
alfacalcidol, calcitriol, and dihydrotachysterol) are
not recommended for routine treatment of
nutritional rickets.
 Daily administration of vitamin D is preferred in
infants. Intermittent administration of vitamin D
may be considered in children and adolescents with
poor compliance with daily treatment (i.e. 50000 IU
weekly for 6–8 consecutive weeks or 100000 IU
monthly for 3–4 consecutive months).
 We recommend against the administration of a
single large dose of vitamin D > 300000 IU.
 After rickets healing, we recommend to continue
vitamin D supplementation according to age
(400–1000 IU/day in the first year of life and
600–1000 IU/day from 1 to 18 years).
Bone health
 Vitamin D directly influences bone mass acquisition
contributing to the regulation of calcium-phosphorus
metabolism, and indirectly stimulating the
development of muscle tissue.
 Available evidence suggests a positive effect of
vitamin D supplementation on bone mass
acquisition in children and adolescents with vitamin
D deficiency.
 Recent studies suggest a relationship between
maternal vitamin D status during pregnancy and
bone mass of the fetus and the newborn. Uncertain
evidence exists on the relationship with bone mass
later in life until the acquisition of bone mass.
Extraskeletal actions of vitamin D
Respiratory infections
 Recent studies suggest an association between
vitamin D deficiency and the severity or the
incidence of respiratory infections in children.
However, because current evidence is weak, we
suggest against vitamin D administration as a
therapy for respiratory infections, beyond the
correction of a documented vitamin D deficiency.
 No definitive evidence exists to recommend vitamin D
supplementation for prevention of respiratory
infections (non-associated with wheezing) or recurrent
respiratory infections. However, some studies suggested
that serum 25(OH)D higher than those needed for the
prevention of nutritional rickets may be necessary to
exert a regulatory effect on the immune system.
 We recommend against routine 25(OH)D testing in
children with respiratory infections.
 A single RCT suggested that vitamin D
supplementation may help in preventing non
complicated acute otitis media. However,
considering this limited evidence, evaluation of
serum 25(OH)D levels may be reasonable before
starting supplementation in these children.
Other infections
 Reduced serum 25(OH)D levels are found in
children with different types of infectious diseases
(tuberculosis, HIV, viral hepatitis, acute diarrhea).
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However, available evidence does not support a
causal relationship between hypovitaminosis D and
infections.
 We suggest the evaluation of vitamin D status only
in patients affected by tuberculosis or HIV infection,
as they may benefit from vitamin D
supplementation, in particular due to concomitant
treatments that influence vitamin D metabolism.
 We recommend against vitamin D supplementation
to reduce incidence or severity of non-respiratory
infections in children. However, as few studies showed
that vitamin D supplementation improves clinical
parameters in patients with active tuberculosis or
HIV infection, more rigorous and extensive studies
are needed to evaluate the role of vitamin D
supplementation in infectious diseases, considering
also the setting of care, children’s age and nutritional
status, potential co-infections and compliance with
anti-infective therapy.
Asthma
 Recent meta-analyses did not find an association
between 25(OH)D levels in cord blood or during
pregnancy and the development of asthma later in life.
 Several studies showed a relationship between
latitude, prevalence of hypovitaminosis D and
increase in allergic asthma prevalence in the
pediatric population.
 Low serum 25(OH)D levels are associated with
increased asthma severity and increased risk of
asthma exacerbations requiring hospitalization or
medical treatment. Recent meta-analyses suggest that
supplementation with vitamin D (500–2000 IU/day)
may reduce the risk of asthma exacerbation.
 We recommend against routine 25(OH)D testing in
children with asthma.
Atopic dermatitis and allergic diseases
 Low serum 25(OH)D levels are associated with
increased incidence and/or severity of AD in
children in most but not all studies. Indeed, a
pathogenetic role of vitamin D in AD has yet to be
demonstrated.
 We recommend against routine 25(OH)D testing in
children with AD. Serum 25(OH)D evaluation may
be considered in children with severe AD
unresponsive to common therapy and multiple risk
factors for vitamin D deficiency.
 In pediatric population there is limited evidence
regarding a possible favourable effect of vitamin D
supplementation on several aspects of AD.
 A short trial of vitamin D supplementation can be
considered in patients with severe AD unresponsive
to common therapy, especially in the late winter-early
spring period. In presence of documented vitamin D
deficiency, we recommended adequate treatment to
restore vitamin D status, followed by supplementation
at doses recommended for age.
 Vitamin D supplementation for primary prevention
of allergic diseases, including food allergies, remains
an attractive area of study, but actual evidence does
not allow to make any recommendation.
Type 1 diabetes mellitus
 Children and adolescents with T1DM are at risk for
vitamin D deficiency.
 Recommended vitamin D intakes in patients with
T1DM are the same as those for the healthy
pediatric population.
 Recommendations for vitamin D treatment in
subjects with T1DM and vitamin D deficiency are
the same as those for the healthy pediatric
population.
 At present, there is no evidence that vitamin D
supplementation may delay the development of
T1DM or may ameliorate its clinical features.
However, we recommend to maintain vitamin D
intake for age and to treat vitamin D deficiency if
found.
 We recommend against routine 25(OH)D testing in
children with T1DM.
Inflammatory bowel diseases
 In patients with IBDs (Crohn’s disease or ulcerative
colitis) we suggest to evaluate serum 25(OH)D levels
at diagnosis and at least yearly, preferably in the late
winter-early spring period.
 We recommend continuous vitamin D
supplementation at higher doses than those
recommended for age (at least 1000–1500 IU/day).
 We recommend to treat vitamin D deficiency with
daily vitamin D at higher doses than those
recommended for otherwise healthy pediatric
population (at least 2000–4000 IU/day), for a
minimum of 6–8 weeks.
 Intermittent bolus doses of vitamin D for a
cumulative dose of at least 400000 IU should be
reserved for IBDs patients with vitamin D deficiency
and poor compliance with daily treatment.
 After achieving vitamin D sufficiency, we
recommend to continue with vitamin D
supplementation at higher doses than those
recommended for age (at least 1000–1500 IU/day).
Celiac disease
 We recommend to evaluate serum 25(OH)D levels
in patients with CD at diagnosis and 6–12 months
after the beginning of gluten-free diet if deficiency
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has been found. We suggest against further
25(OH)D evaluations in case of sufficient 25(OH)D
levels or documented normalization of vitamin D
status and strict adherence to the gluten-free diet.
 Recommendations for treatment of vitamin D
deficiency in patients with newly diagnosed CD are
equivalent to those for IBDs patients, as both these
conditions are associated with intestinal malabsorption.
 As gluten-free diet restores normal intestinal
absorption, after treatment of deficiency we
recommend vitamin D supplementation according
to the modalities and requirements for otherwise
healthy children and adolescents.
Obesity and metabolic syndrome
 Epidemiological studies showed that obese children
and adolescents are at high risk for vitamin D
deficiency.
 Obesity is the cause and not the effect of this
association because of the deposition of vitamin D
in adipose tissue with consequent reduction in
serum 25(OH)D levels.
 It is uncertain if vitamin D deficiency may worsen
metabolic profile of obese children and adolescents.
 We suggest against vitamin D administration to
improve obesity-related complications, given incon-
sistent results and the small number of studies.
 We suggest vitamin D supplementation at higher
doses than those recommended for age (1000–
1500 IU/day) from the end of fall to the beginning
of spring (November–April) in obese children and
adolescents to ensure an adequate vitamin D status.
Obese subjects with reduced sun exposure during
summer should receive vitamin D supplementation
throughout the year. Finally, sensible sunlight
exposure and outdoor physical exercise should be
encouraged in obese children and adolescents.
 We recommend against routine evaluation of
25(OH)D levels in obese subjects. If an obese
individual does not receive vitamin D
supplementation and has a sedentary indoor lifestyle
with consequent reduced sun exposure, serum
25(OH)D evaluation may be considered to confirm
vitamin D deficiency and start adequate treatment.
 In obese subjects with vitamin D deficiency we
recommend vitamin D treatment at higher doses
than those recommended for otherwise healthy
pediatric population (at least 2000–4000 IU/day), for
a minimum of 6–8 weeks.
Autism
 Autistic individuals frequently develop nutritional
deficiencies, especially in presence of food selectivity;
causal relationship with vitamin D deficiency is
uncertain.
 We recommend against routine evaluation of
25(OH)D levels in children with autism.
 We recommend against vitamin D treatment to
improve patient’s performance considering the
limited and conflicting available evidence.
Depression
 Epidemiological studies that evaluated an association
between vitamin D deficiency and depression are
lacking at present.
 We recommend against routine evaluation of
25(OH)D levels in children with depression.
 We recommend against vitamin D administration to
improve mood.
Pregnancy and breastfeeding
 We suggest against routine screening of serum
25(OH)D levels in all pregnant and breastfeeding
women. We suggest to consider serum 25(OH)D
testing in women with multiple risk factors for
vitamin D deficiency, particularly if not receiving
vitamin D supplementation, and/or with specific
conditions possibly affecting pregnancy course
(Table 9).
 We recommend vitamin D supplementation in all
pregnant and breastfeeding women at a dose of
600 IU/day. Women with risk factors for vitamin D
deficiency should receive higher dosages
(1000–2000 IU/day).
 We suggest to start vitamin D supplementation at
the beginning of pregnancy and continue for the
entire duration of pregnancy and lactation.
Appendix. Management of asymptomatic vitamin D
deficiency and insufficiency
 In children and adolescents with asymptomatic
vitamin D deficiency [25(OH)D < 20 ng/ml] we
recommend the administration of 2000 IU/day or
50000 IU/week of vitamin D2 or D3 for 6–8 weeks
(8 weeks in adolescents) in order to obtain a
sufficient vitamin D status [25(OH)D ≥ 30 ng/ml].
 After completion of treatment, serum 25(OH)D
concentrations should be revaluated.
 In presence of adequate vitamin D status
[25(OH)D ≥ 30 ng/ml], we recommend to continue
vitamin D supplementation as recommended
for age.
 In subjects with asymptomatic vitamin D deficiency
assuming drugs interfering with vitamin D
metabolism (anticonvulsants, oral corticosteroids,
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antifungals like ketoconazole, anti-retroviral drugs)
we recommend vitamin D treatment at higher doses
than those recommended for otherwise healthy
pediatric population (at least 2000–4000 IU/day), for
a minimum of 6–8 weeks.
 Considering available evidence, particularly the lack
of Italian studies, at present we do not recommend
other modalities different from daily or weekly
administration of vitamin D to treat asymptomatic
vitamin D deficiency.
 In case of detection of asymptomatic vitamin D
insufficiency [25(OH)D between 20 and 29 ng/ml],
particularly in subjects at risk for vitamin D
deficiency, we recommended to start vitamin D
supplementation according to the modalities and
requirements recommended for age.
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